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Vasoactive agents are frequently 
needed in the treatment of septic 
shock and brain death organ donors. 
We evaluated the differences of 
several vasopressors on splanchnic 
blood perfusion and metabolism. 
Even though the systemic blood 
pressure was restored  effectively, 
the splanchnic hemodynamic and 
metabolic profiles differed remark-
ably between different vasoactive 
agents. The specific regional blood 
perfusion deficits were practically 
impossible to evaluate from the sys-
temic parameters.
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ABSTRACT 
Background: Vasoactive agents are frequently needed in the treatment of septic shock 
and in the management of brain dead organ donors. However, the effects of vasopressors 
on splanchnic blood perfusion and metabolism remain controversial. We wanted to 
evaluate the effects and differences of several vasoactive agents on systemic and 
splanchnic blood perfusion and metabolism in septic shock and after brain death. 
Materials and methods: We used experimental porcine models. Anesthetized animals 
were extensively instrumented for collecting blood samples and monitoring the regional 
hemodynamics and metabolism. Septic shock was induced with an endotoxin infusion, 
aiming to cause hypotensive shock. Vasopressor infusion was aimed to increase systemic 
blood pressure to a predetermined level for 4-14 hours.  
The brain death was performed with an inflatable subdural balloon. Systemic 
hypotension was treated with dopamine or vasopressin for five hours. Regional 
hemodynamics and metabolism were monitored similarly to a septic shock model.  
Results: 1) Dopexamine increased the systemic and superior mesenteric arterial blood 
flow (Qsma) but decreased the fractional celiac trunk blood flow, while the gastric 
mucosal pCO2 gradient incresed. 2) Vasopressin decreased the systemic and Qsma blood 
flow and caused systemic and regional lactate release. 3) Hypoperfusion and regional 
lactate release caused by vasopressin were reversed when combined with dobutamine. 4) 
Epinephrine caused severe arterial lactatemia, increased the gastric venous-to-arterial 
CO2 content gradient and had a tendency to increase the gastric lactate gradient. 5) 
Norepinephrine did not cause systemic or regional hypoperfusion. 6) Vasopressin 
decreased the systemic and Qsma blood flow and oxygen delivery after brain death, 
while these adverse effects were not associataed with dopamine.  
Conclusions: Dopexamine redistributed the splanchnic perfusion by retrieving the 
colonic but compromising the gastric blood flow. Vasopressin caused systemic and 
especially mesenteric hypoperfusion, while the adverse effects of vasopressin were 
reversed when combined with dobutamine. Systemic arterial hyperlactatemia associated 
with epinephrine is not explained solely by hypoperfusion, but epinephrine did induce 
selective hypoperfusion to the gastric mucosa. Norepinephrine was not correlated to any 
harmful effect on systemic or regional blood perfusion or metabolism. Dopamine is 
superior to vasopressin in securing small bowel blood perfusion after brain death. 
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TIIVISTELMÄ 
Tausta: Septisessä sokissa ja aivokuolleen elinluovuttajan verenkierron hoidssa tarvitaan 
usein vasoaktiivista lääkitystä. Tutkimustulokset niiden vaikutuksista vatsaonteloalueen 
verenkiertoon ja aineenvaihduntaan ovat kuitenkin ristiriitaisia. Tutkimussarjarjan 
tarkoitus oli selvittää koe-eläinmallilla eri vasoaktiivisten lääkkeiden vaikutukset 
vatsaonteloalueen verenkiertoon ja aineenvaihduntaan septisessä sokissa ja 
aivokuoleman jälkeen.  
Materiaalit ja menetelmät: Koe-eläimenä käytettiin sikaa. Nukutetut eläimet 
instrumetoitiin laaja-alaisesti verinäytteiden keräämistä ja alueellisten verenkierto- ja 
aineenvaihdunta-muutosten monitorointia varten. Septinen sokki aiheutettiin 
endotoksiini-infuusiolla tavoitteena hypotensiivinen sokki. Vasoaktiivinen lääkitys 
aloitettiin 4-14 tunnin ajaksi tavoitteena nostaa verenpaine ennalta määrätylle tasolle.  
Aivokuolema aiheutettiin kovakalvon alle asetetulla, täytettävällä pallolla. 
Vasopressiinia tai dopamiinia annettiin viiden tunnin ajan systeemisen verenpaineen 
hoitamiseen. Alueellisia verenkierron ja aineenvaihdunnan muutoksia monitoroitiin 
samankaltaiseseti kuin sepsis-mallissa.  
Tulokset: 1) Dopeksamiini lisäsi sydämen minuuttitilavuutta ja ylemmän 
suolivaltimon verenvirtausta, mutta vähensi yhteisen suolivaltimorungon verenvirtausta 
ja nosti mahalaukun limakalvon hiilidioksidigradienttia. 2) Vasopressiini vähensi 
sydämen minuuttivirtausta ja ylemmän suolivaltimon verenvirtausta ja aiheutti 
alueellista laktaatin vapautumista. 3) Dobutamiini korjasi vasopressiinin aiheuttaman 
verenkiertovajauksen ja esti haitalliset aineenvaihdunnan muutokset. 4) Adrenaliini 
aiheutti laktatemian, sekä hiilidioksidipitoisuuden ja laktaattigradientin kasvamisen 
mahlaukun alueella. 5) Noradrenaliini ei aiheuttanut systeemistä tai paikallista 
verenkierron vajausta eikä haitallisia aineenvaihdunnan muutoksia. 6) Vasopressiini 
vähensi sydämen minuuttivirtausta ja ylemmän suolivaltimon verenvirtausta ja 
hapentarjontaa, kun taas dopamiinin käyttöön ei liittynyt haitallisia vaikutuksia 
aivokuoleman jälkeen.  
Johtopäätökset: Dopeksamiini aiheutti vatsaonteloalueen verenkierron 
uudelleenjakautumista palauttaen paksusuolen, mutta vaarantaen mahalaukun 
verenvirtauksen. Vasopressiini aiheutti sydämen minuuttivirtauksen vähenemisen ja 
etenkin ohutsuolen verenkiertovajauksen. Nämä muutokset korjaantuivat, kun 
vasopressiinin rinnalle yhdistettiin dobutamiini. Yksinomaan verenkiertovajaus ei selitä 
adrenaliinin aiheuttamaa laktatemiaa, mutta adrenaliini aiheutti selektiivisesti 
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mahalaukun verenkierron vajauksen. Noradrenaliinin käyttöön ei liittynyt haitallisia 
systeemisiä tai alueellisia vaikutuksia verenkierrossa tai aineenvaihdunnassa. Dopamiini 
on vasopressiinia parempi ohutsuolen verenkierron turvaamisessa ainokuolleella 
elinluovuttjalla. 
 
Yleinen suomalainen asiasanasto: aivokuolema; elimensiirto – ohutsuoli; koe-eläimet – 
sika; septinen sokki; verenkierto – ohutsuoli 
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1 Introduction 
 
This review focuses on two different disorders, septic shock and 
hemodynamic managementȱ of brain dead organ donors. Similarities 
between the two conditions include, but are not limited to, the 
apparent fact that both systemic and, especially, splanchnic blood flow 
is frequently compromised. In septic shock, vasoactive agents are 
regularly used to support systemic and, supposedly, splanchnic blood 
flow. After brain death, over 80% of patients need vasoactive 
medication, due to systemic hypotension (Nygaard 1990). Thus, 
presumably, splanchnic blood flow also decreases, compromising the 
vitality of the small bowel. The choice of vasoactive medication and its 
effects on tissue perfusion and metabolism may play a major role in 
both of these disorders.  
Despite the better understanding and improved treatment 
interventions, septic shock is still one of the leading causes of mortality 
in intensive care units (Christaki and Opal 2008). The pathogenesis of 
septic shock is still partly unclear, but its typical manifestations 
include tissue hypoperfusion and the activation of proinflammatory 
cascades (Deitch 1992). If fluid resuscitation fails to maintain the 
systemic and splanchnic perfusion, vasoactive agents are frequently 
needed. However, despite the extensive research, there is still 
discrepancy on which, if any, vasoactive agent is superior in the 
securing of systemic or splanchnic perfusion (Hollenberg 2007). 
Splanchnic hypoperfusion may cause intestinal mucosal injury, 
leading to the breakdown of gut barrier function and thus allowing 
bacteria and bacterial toxins access to systemic circulation or the 
lymphatic system (Rotstein 2000, Deitch et al. 2006). One remedy to 
prevent the development of multiple organ dysfunction syndrome 
(MODS) may be securing splanchnic circulation in order to normalize 
cellular metabolism. A relevant clinical method to evaluate splanchnic 
perfusion does not exist, and the assessment of splanchnic 
microcirculation is even more complex.  
Another typical clinical scenario in critical care where vasoactive 
agents are frequently needed, in addition to the other treatment 
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modalities, is the management of brain dead organ donors (Shah 
2008). There is a discrepancy between the patients needing the organ 
transplantation and the availability of potential organ donors. Small 
bowel transplantations from brain dead organ donors have been 
successfully performed. However, blood perfusion and the vitality of 
the intestine deteriorate after the brain death (Golling et al. 2003). 
Therefore, the aggressive management of maintaining the systemic 
and splanchnic tissue perfusion and thereby organ functions of organ 
donors is crucial.  
We performed series of experiments on the porcine endotoxin 
shock model. We wanted to evaluate the systemic, and especially 
regional, hemodynamic and metabolic effects of dopexamine, 
vasopressin, norepinephrine, epinephrine and vasopressin combined 
with dobutamine.  We also focused on the effects of dopamine and 
vasopressin on mesenteric blood perfusion and metabolism after brain 
death.     
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2 Review of the literature 
2.1 SPLANCHNIC TISSUE PERFUSION 
The ȱ tasks  ȱof ȱ the ȱ intestinal ȱ system  ȱcan  ȱbe divided into  two 
different functions: to digest and absorb nutrients and to maintain a 
bacterial barrier between the bowel and the blood stream (or the bowel 
and the lymphatic system). These functions require adequate and 
constant macro- and microvascular splanchnic perfusion. The 
splanchnic blood flow is the sum of the hepatic arterial and portal 
blood flow. Portal blood flow is the sum of blood flows from the 
stomach, spleen, pancreas, intestines and mesentery.    
2.1.1 Anatomy of splanchnic circulation 
Splanchnic vasculature ȱconsists of threeȱȱmajor arterial branches, 
stemming from the aorta: celiac trunk, superior mesenteric artery 
(SMA) and inferior mesenteric artery (IMA) (Pennington and Soames 
2005) (Figure 1). The celiac trunk supplies blood flow to the stomach, 
liver, and spleen. It arises from the aorta as a single vessel, soon 
dividing into three branches in 91% of individuals. The branches of the 
celiac trunk include the splenic artery, common hepatic artery and left 
gastric artery. There are several possible anatomical variations of the 
celiac trunk and SMA, whereas the variations of IMA are less common 
(Yi et al. 2008).   
 
              
 
Figure 1.  Major abdominal arteries.  
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The largest branch of the abdominal aorta is the superior 
mesenteric artery (SMA). It supplies arterial blood to the entire small 
intestine. The SMA also supplies blood to the ascending and 
transverse colon and the pancreas, whereas the IMA supplies blood to 
the descending colon and cecum. In the small intestine, the mesenteric 
arterioles form the mesenteric arcade, where the arterioles further 
divide into three layers: muscular, submucosal and mucosal. In a 
fasting animal, the blood supply divides approximately as follows: 
mucosal 70-80%, muscular 15-25% and submucosal 5%. Mucosal 
arterioles form vessels that terminate as end loops. They supply 
approximately 60% of the mucosal blood flow to the epithelial cells in 
the intestinal villi, while the rest of the mucosal blood supplies the 
crypts and goblet cells. The artery and vein in the villus are closely 
parallel, and the artery divides into a capillary network at the top of 
the villus (Figure 2.). This anatomical speciality allows for the 
possibility of oxygen to be transported straight from the artery to the 
vein, without reaching the tip of the villus. This phenomenon is called 
counter current exchange, and it causes the partial pressure of oxygen 
to decrease at the top of the villus (Lundgren and Haglund 1978). 
Therefore, the villi of the jejunum are vulnerable to hypoxia and injury 
if perfusion to the jejunal wall is compromised in any way.  
 
 
 
 
Figure 2. Cross section of intestinal villus. 
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The gastric arterial blood supply arises from four main arterial 
branches:  the left and right gastric arteries and the left and right 
gastroepiploic arteries. In addition, there are several other 
anastomoses and variants in the gastric arterial bed (Vandamme and 
Bonte 1988, Gregorczyk et al. 2008). As a result, absolute gastric blood 
flow is very challenging to measure. Gastric mucosal blood flow and 
its regulation are not fully understood. There is evidence that poor 
gastric microcirculation exposes one to gastric ulcerations, whereas 
adequate perfusion has a protective effect (Abdel-Salam et al. 2001). 
Several vasoactive agents, such as prostaglandins, nitric oxide and 
sensory neuropeptides, are thought to play crucial roles in the gastric 
mucosal defense (Gyires et al. 2005).  
2.1.2 Regulation of splanchnic perfusion 
Within normal physiologic conditions, 20-25% of the cardiac  output 
(CO) flows through  the celiac trunk and superior and inferior 
mesenteric arteries. However, intestinal ȱblood flow can dramatically
alter  within    normal    physiological conditions, asȱȱduring nutrient 
absorption.   For  example,  intestinal mucosal blood flow may increase 
by   200%    during   digestion.  This  is possible by the recruitment of 
previously  closed capillaries  in  the gut mucosal layer   (Matheson et 
al. 2000).  
There are several factors that regulate splanchnic perfusion, and 
they can be divided into vasodilators or vasoconstrictors. Common to 
these vasoactive mediators is the fact that vasodilators decrease 
cytosolic free calcium, whereas vasoconstrictors increase intracellular 
free calcium (Moreau and Lebrec 2001).  
The transmembrane potential of the smooth muscle cell 
cytoplasmic surface of a resting cell membrane is negative (around -
50mV), and it is determined by potassium and (Na+/K+)-ATPase 
(Ashcroft and Ashcroft 2001). Since the intracellular K+ concentration is 
much higher than the extracellular concentration, it favors the efflux of 
K+. Efflux is controlled by three types of K+ channels: the ATP-sensitive 
K+ (KATP) channel, the delayed rectifier K+ channel, and the Ca2+ -
activated K+(KCa) channel (Hirst, Edwards 1989). The extracellular Ca2+ 
concentration is much higher than free cytosolic Ca2+. This 
concentration gradient favors extracellular Ca2+ entry into the smooth 
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muscle cell. Two subgroups of Ca2+ channels control this influx: 
voltage-dependent Ca2+ channels and voltage-independent Ca2+ 
channels. In arterial smooth muscle cells, the voltage-dependent Ca2+ 
channels are mainly of the long-acting (L)-type, which can be blocked 
by certain dihydropyridines, such as nifedipine (McDonald et al. 
1994).   
2.1.2.1  Vasodilation 
Vasodilator substances, such as nitric oxide (NO) and prostacyclin 
(PGI2), come from the blood stream or are released from the 
endothelium. In addition, non-sympathetic nerve-endings release 
vasodilator substances. There is a constant release of NO from 
endothelium caused by pulsatile flow and shear stress. NO causes 
vasodilation by activating cyclic GMP (cGMP), which activates the 
cGMP –dependent protein kinase. This, in turn, reduces intracellular 
Ca2+.  PGI2 is also released from the endothelium, and it activates 
adenyl cyclase to produce cyclic AMP (cAMP). cAMP activates cGMP 
and causes vasodilatation by reducing intracellular Ca2+ (Moncada et 
al. 1991). cGMP can reduce Ca2+ by at least three different mechanisms. 
First, it stimulates Ca2+ pumps, which push Ca2+ outside the cell or into 
the sarcoplasmic reticulum. Second, it decreases Ca2+ entry to the cell. 
Third, cGMP may decrease the release of Ca2+ by inhibiting inositol 
1,4,5-triphosphate (insP3) (Lincoln and Cornwell 1993).  
In addition to NO and PGI2, there are several other substances that 
cause vasodilation. For example, atrial natriuretic peptides, glucagon, 
adenosine, histamine, neuropeptides and β2-adrenoreceptor 
stimulators have vasodilator effects (Bevan and Brayden 1987).  
2.1.2.2 Vasoconstriction 
Vasoconstriction is mediated by specific receptors (α1, V1a, AT1, ETA –
receptors) located in the surface of vascular smooth muscle cells 
(Schrier et al. 1993, Griendling et al. 1993). Despite their wide 
diversity, the mechanisms of these receptors are very similar. They 
belong to the superfamily of guanosine triphosphate (GTP) –binding, 
protein-linked receptors. The molecular structure contains seven 
domains spanning the cellular membrane, which are connected with 
intra- and extracellular loops. When the agonist binds to the receptor, 
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intracellular Ca2+ mobilizes and extracellular Ca2+ enters the cell. 
This, in turn, causes smooth muscle contraction (Moreau and Lebrec 
2001).    
Norepinephrine causes vasoconstriction by stimulating α1 –
receptors in both arterial and venous vessels both systemically and 
also in the splanchnic area. However, it seems not to have detrimental 
effects on splanchnic (Guérin et al. 2005) or renal blood perfusion 
(Albanèse et al. 2004). It also has a weaker affinity to β –receptors, and 
therefore may increase cardiac output.  Vasopessin has three subtypes 
of receptors: V1, V2 and V3. Vasoconstriction is mediated via V1 
receptors, and they are located in various tissues, including the liver, 
skin, skeletal muscle and mesenteric blood vessels. V2 receptors 
mediate water retention and are located in the collecting duct of the 
kidney. V3 receptors modulate corticotrophin secretion from the 
adenohypopfysis (Treschan and Peters 2006).  AT1 –receptors are 
located in vascular smooth muscle cells, the lungs, liver, brain, kidney, 
heart and liver (Griedling et al. 1996).  
2.1.2.3  Hepatic blood flow and arterial buffer response 
Hepatic blood flow, i.e. blood perfusion through the liver, is the sum 
of hepatic arterial (Qha) and portal venous (Qporta) blood flows. The 
portal blood flow is basically mesenteric arterial (superior and inferior) 
blood flow, which is determined by vascular resistance across the 
intestine. Hepatic arterial blood flow, in turn, is determined by hepatic 
arterial resistance. (Takala 1996, Richardson 1982).  
The major intrinsic regulator of hepatic arterial blood flow is portal 
blood flow. If portal blood flow is altered, hepatic arterial resistance 
changes in order to keep total hepatic flow constant. Hepatic arterial 
blood flow can compensate for a decrease in portal venous blood flow 
of up to 30%. This response is called a hepatic arterial buffer response 
(HABR), and it seems to depend on the concentrations of adenosine 
(Lautt 1985).  
In some cases, the extent of HABR may be diminished. Such 
conditions include experimental endotoxin shock (Ayuse 1995) and 
thereby presumably septic shock. In addition, Jakob et al. tested the 
hepatic arterial buffer response in the partial mesenteric arterial 
occlusion model and cardiac tamponade model. They discovered that 
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HABR decreased significantly during partial mesenteric ischemia 
(Jakob et al. 2002a) and in severe tamponade (Jakob et al. 2001). They 
concluded that ischemia/reperfusion may have interfered with hepatic 
adenosine production or transport and that the liver is only initially 
protected during low systemic perfusion.  
HABR is an important mechanism to preserve hepatic blood flow 
and oxygen supply. However, if the splanchnic perfusion has already 
decreased, then a new acute decrease in splanchnic blood flow may 
not be compensated by HABR, thus leading to hepatic failure (Jakob 
2002).  
2.1.3 Assessment of splanchnic tissue perfusion 
Because of the complex anatomy and physiology of splanchnic 
vasculature and circulation, the direct measurement of splanchnic 
tissue perfusion is practically impossible without surgery. Therefore, 
human studies measuring splanchnic blood flow are rare. Several 
experimental studies have been made to evaluate basic physiological 
splanchnic circulation. The only clinical method to evaluate total 
hepatosplanchnic blood flow is by the Fink principle. Perfusion is 
estimated with substances that are metabolized only by the liver and 
distributed to plasma. It also requires a hepatic vein catheterization. 
Uusaro et al. have published a study using this technique in intensive 
care patients (Uusaro et al. 1995). However, there are some pitfalls, 
and caution should be used if splanchnic perfusion is interpreted with 
this method. Other, indirect techniques, for the evaluation of 
splanchnic perfusion include laser Doppler flowmetry, 
spectrophotometry, gastric tonometry and magnetic resonance 
imagining (Jakob, Takala 2002).  
Barthelmes et al. used the latter in nine healthy volunteers to 
evaluate somatostatin-induced blood perfusion changes in the aorta, 
superior mesenteric artery, celiac trunk, hepatic arteries, and portal 
vein (Barthelmes et al. 2009). The authors concluded that  blood   flow 
changes in  the   splanchnic region were reliably detected by MRI, and it 
may be useful for  the  noninvasive assessment of blood flow changes in 
the splanchnic region. Understandably,  this  cannot be considered to be 
a bedside method or suitable for continuous measurement of splanchnic 
perfusion.  
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Fiddian-Green et al. described the technique of gastric tonometry in 
1982 (Fiddian-Green et al. 1982). At the beginning of the 1990s, gastric 
tonometry seemed a promising, relatively non-invasive method to 
evaluate splanchnic perfusion. Gastric intramucosal pH appeared to 
have a high specificity for predicting patient survival in an ICU patient 
population (Doglio et al. 1991). However, this correlation has been 
questioned by many authors (Creteur et al. 1999, Holm et al. 2006).  
Gastric tonometry is based on the idea of measuring the gastric 
luminal partial pressure of CO2 (or the difference between gastric 
mucosal pCO2 and arterial pCO2) or the pH with saline or an air filled 
balloon. Changes in CO2 or pH are thought to indirectly indicate 
changes in gastric perfusion. Changes in gastric perfusion, on the other 
hand, have thought to imitate the whole splanchnic perfusion. 
However, there are several questions concerning this extrapolation. As 
stated previously, splanchnic vasculature is very complex, and there 
may be a redistribution of blood flow within the splanchnic area. Also, 
there may be alterations within gastric microcirculation that do not 
correlate to the entire splanchnic perfusion. Therefore, gastric blood 
flow does not necessarily reflect the total splanchnic perfusion. Other 
questions arise from the physiology of gastric CO2. CO2 molecules 
originate from gastric mucosa (a function of arterial CO2 and CO2 
added by metabolism) by diffusion or by the HCO3- titration by the 
acid (lactate) present in the stomach. If regional flow is decreased, 
gastric tissue CO2 content must rise even if intracellular acidosis is 
absent. Gastric CO2 may be increased not only by hypoperfusion but 
also by CO2 originating from the esophagus or mucosa of ileum. Also, 
gastric intraluminal changes of HCO3- (from reflux), which are not 
measurable from arterial blood, may change the partial pressure of 
CO2 (Carlesso et al. 2006). Due to these sources of uncertainties, the 
use of tonometry has diminished in clinical work.  
It is well known that septic shock alters microcirculatory perfusion 
and the permeability of the capillary vessels. However, it is 
challenging to estimate the gut mucosal microcirculation without 
invasive monitoring. Verdant et al. compared sublingual and gut 
mucosal microcirculation in seven septic pigs with a modified 
orthogonal polarization spectral device by measuring functional 
vascular density and erythrocyte velocity (Verdant et al. 2009). The 
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correlation of the microvascular changes between these two areas was 
high (r = 0.92, p < 0.0001), and the authors concluded that the 
sublingual area could be a good region to monitor the microcirculatory 
changes associated with septic shock. Boerma et al. used the same 
method in patients with abdominal sepsis (Boerma et al. 2007). They 
found that the correlation between sublingual and intestinal 
microcirculation tended to be restored after only three days of sepsis, 
therefore questioning the relevance of the method for monitoring the 
microcirculation of septic patients.  
 
2.2  SEPSIS AND SEPTIC SHOCK 
2.2.1 Epidemiology and etiology 
In the beginning of the 1990s, severe sepsis was defined as the 
presence of infection, a systemic inflammatory response and acute 
organ dysfunction by the American College of Chest Physicians 
(ACCP) and the Society of Critical Care Medicine (SCCM) (Bone et al. 
1992). Uniform definitions for systemic inflammatory response 
syndrome (SIRS); sepsis; severe sepsis; and, its most devastating form, 
septic shock were redefined by the International Sepsis Definitions 
Conference in 2001 (Levy et al. 2003). The original criteria of SIRS 
include at least two of the following criterion: a core temperature < 36 
ºC or > 38 ºC, heart rate > 90/min, respiratory rate > 20/min or PaCO2 < 
4.3 kPa, white blood cell count > 12x109 or < 4 x 109 /L. The abridged 
definitions of sepsis are stated in Table 1.  
 
Table 1. Criteria for infection, sepsis, severe sepsis and septic shock. 
 
Infection A pathologic process caused by the invasion of 
normally sterile tissue or fluid or body cavity by 
pathogenic organism 
Sepsis The clinical syndrome defined by the presence of 
both infection and a systemic inflammatory response 
Severe sepsis Sepsis complicated by organ dysfunction 
Septic shock Severe sepsis plus a state of acute circulatory failure 
characterized by persistent arterial hypotension 
unexplained by other causes and despite adequate 
volume resuscitation. 
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Sepsis is a common syndrome that burdens heath care world wide. 
Sepsis and septic shock are two of the leading causes of morbidity and 
mortality in ICUs (Martin et al. 2000). Several epidemiological studies 
on sepsis have been performed recently, and their conclusions show 
that the incidence of severe sepsis is slowly climbing and seems to be 
up to 30% among ICU patients (Silva et al. 2004, Flaatten 1999, vas 
Gestel et al. 2004, Blanco et al. 2008). Despite advanced diagnostics and 
treatment, the mortality of severe sepsis is high, from 28% to 49% 
(Angus et al. 2001, Dombrovskiy et al. 2003). According to a 
prospective, multicenter FINNSEPSIS study, the incidence of severe 
sepsis in Finland requiring intensive care treatment was 0.38/1000 
adults per year. The mortality of sepsis was 15.5% in the ICU, 28.3% in 
hospitals, and 40.9% during the first year (Karlsson et al. 2007).   
The most common sources of septic shock are the lungs (25%) and 
abdomen (25%).  The causing bacteria or fungi are not always caught 
in the blood cultures. According to Rodríguez-Créixems et al., gram-
positive and -negative bacteria cause an approximately equal number 
of infections (15.7/1000 vs. 16.2/1000 admissions, respectively), 
whereas anaerobes (1.3/1000 admissions) and fungi (1.5/1000 
admissions) are less common yet often lethal pathogens (Rodríguez-
Créixems et al. 2008).  
2.2.2 Inflammatory cascade in sepsis 
Even though the pathophysiology of sepsis and septic shock and the 
most dreadful sequelae of septic shock, MODS, has been extensively 
studied, absolute understanding is still lacking. In the mid 1980s, Goris 
et al. suggested that the development of MODS involves the massive 
activation of inflammatory mediators, resulting in systemic damage to 
vascular endothelia and permeability edema and impaired oxygen 
availability to the mitochondria, despite adequate oxygen transport 
(Goris et al. 1985).  
Indeed, evidence today suggests that that a massive inflammatory 
reaction, resulting from systemic cytokine release, is the common 
pathway underlying sepsis and MODS (Tsiotou et al. 2005). However, 
to date, it has been impossible to point to a specific cytokine or 
reaction as the cause of MODS. The sheer number of different 
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cytokines, with their different temporal actions in relation to disease 
state, makes them difficult to study. Distinguishing between 
deleterious reactions and beneficial healing processes during the 
course of organ failure is demanding, if not impossible. Cytokine 
release is a normal part of the body’s response to infection. However, 
cytokines are capable of producing significantly different effects, 
depending on the local hormonal surroundings. The network of 
receptor antagonists and other agents are able to continuously 
modulate the effects of cytokines. Moroever, cytokine release can 
occur in variety of disorders without leading to organ dysfunction. In 
addition, during clinical manifestations of MODS, the pattern of 
systemic cytokine release is often different based on the experimental 
setting (Bone et al. 1997). More than 100 molecules have been 
proposed as biological markers or effector molecules of sepsis, and 
TNF-alpha, IL-6, chemokines and cytokines are considered the first line 
factors (Gullo et al. 2010). It seems that a constant high level of 
cytokines predict the development of MODS and mortality better than 
peak levels (Pinsky et al. 1993, Pinsky 1994). In septic patients, the 
normal cytokine response regulated by a complex network of pro- and 
anti-inflammatory mediators is diminished. Even though specific 
antagonists for a single proinflammatory agent have shown to reduce 
the inflammatory responses in experimental models (Zhang et al. 2010, 
Hagiwara et al. 2009, Nishiyama et al. 2009), in clinical studies, 
improving the outcome of sepsis with antagonists have failed (Ianaro 
et al. 2009).  
The function of the cell-mediated immune response is often 
compromised in the course of sepsis. CD4 T cells express both 
inflammatory (for example, TNF-α, interleukin-2) and anti-
inflammatory (interleukin-4 and interleukin-10) cytokines, but it is 
unknown which mediators cause T-cells to determine the alternative 
cytokine release (Hotchkiss and Karl 2003). There is some evidence 
that increased anti-inflammatory cytokine levels (Gogos et al. 2000) 
and a failure of T cells to respond to the antigens (i.e. anergy) may be 
correlated with higher mortality in sepsis (Heidecke et al. 1999). 
Anergy may be initiated by apoptotic cell death, which seems to be 
common among lymphocytes and gastrointestinal epithelial cells 
(Hotchkiss et al. 1999). In particular, lymphocyte apoptosis, rather than 
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necrosis, seems to play important role in patients who die of severe 
sepsis because of the depletion antibody production, macrophage 
activation and antigen presentation.  
Obviously, neutrophils also play a pivotal role in the course of 
sepsis. Neutrophils have both beneficial and injurious influences: they 
have an ability to eliminate pathogens but also are able to release 
oxidants and proteases that may be responsible for organ failure. 
However, studies focusing on enhancing neutrophil count or function 
have failed to improve chances of survival from sepsis.  
The high-mobility group box 1 (HMGB-1) protein acts as a 
proinflammatory cytokine, and it may be released by neutrophils and 
monocytes contributing to the inflammatory response in septic shock. 
The HMGB-1 levels are often elevated in septic shock, and the 
concentration levels seem to be correlated with the degree of organ 
dysfunction (Gibot et al. 2007). In the Finnish multicentre study, 
Karlsson et al. noticed that HMGB-1 levels were elevated in patients 
with severe sepsis but did not predict hospital mortality (Karlsson et 
al. 2008).   
Histones are proteins that form a core around DNA, and they 
possess a key role in gene modification. Recently, it has been shown 
that extracellular histones may contribute to the progression and the 
outcome of septic shock by having the capability to kill cells (Xu et al. 
2009). Activated protein C (APC) cleaves the structure of the histones, 
and the use of APC decreases the toxicity of the histones. 
The participation of endotoxin in the development of gram-
negative septic shock is virtually undisputed. Endotoxin is a 
component of the outer membrane of all gram-negative bacteria. When 
the invasion of an endotoxin is detected by the defense molecules of 
the host immune system, a cascade of inflammatory responses is 
initiated. This often leads to a massive release of cytokines (such as 
TNF-α and IL-1β) in order to eliminate the invasive pathogens. This 
reaction of the immune system may lead to a generalized systemic 
inflammatory response. However, the therapies to control the cytokine 
release have failed to improve the outcomes to septic shock, probably 
instead placing the patients at risk of overwhelming infection (Horn et 
al. 2000).  
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2.2.3 Splanchnic tissue perfusion in septic shock 
The clinical hemodynamic characteristics of septic shock are 
hypotension, tachycardia, increased cardiac output, cold (or warm in 
progression of shock) periphery, low central venous pressure and poor 
diuresis. If not treated, vasodilatation and increased vascular 
permeability cause relative hypovolemia, eventually leading to 
inadequate organ perfusion. In particular, splanchnic hypoperfusion 
has been implicated as a motor of septic shock. It has been widely 
studied since the 1960s, when Scweinburg et al. suggested that gut-
mediated endotoxins could contribute to sepsis (Scweinburg and Fine 
1960). The “gut hypothesis” is proposed as a primary hypoperfusion 
and the hypoxia of a gut. As a result of hypoxia, the tissue is damaged 
and the mucosal barrier breaks down and allows gut luminal bacteria 
and its components to access the systemic circulation. Also, an 
ischemia-reperfusion injury of the gastrointestinal tract following 
hypoxia may cause the massive release of cytokines and other 
proinflammatory mediators.  
Splanchnic perfusion is typically increased in the early state of 
sepsis. It is associated with higher splanchnic oxygen extraction and 
consumption, but the changes are unpredictable from systemic 
changes (Dahn et al. 1987, Ruokonen et al. 1993, Arvidsson et al. 1991). 
In septic shock, however, splanchnic and especially mesenteric arterial 
blood flow changes are unclear, since clinical studies are lacking. 
According to experimental models, it seems that mesenteric arterial 
blood flow and oxygen delivery are reduced in septic shock, and this 
may be an important factor leading to gut epithelial permeability 
disorder (Fink 1993).  
Like splanchnic perfusion, liver blood flow can also not be judged 
by systemic hemodynamics. At the early stages of septic shock, in 
addition to increased splanchnic perfusion, hepatic blood flow also 
usually increases. Still, hepatic tissue can become ischemic. This is 
explained by high splanchnic oxygen demand and disproportionally 
high oxygen consumption, due to hepatic hypermetabolism (Dahn et 
al. 1990).   
In addition to changes in macrocirculation, sepsis causes severe 
changes in microcirculatory blood flow in splanchnic organs. The 
alterations of microcirculation cannot be estimated from either the 
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systemic or even the regional blood flow. Hiltebrand et al. 
demonstrated this in an experimental septic shock model, in which 
systemic and regional perfusion decreased dramatically during the 
early stages of septic shock (Hiltebrand et al. 2000). With fluid 
resuscitation systemic and  regional  blood flow increased 
approximately three-fold, but hepatic microcirculation barely reached 
the baseline.  Hepatic microcirculatory alterations could be explained 
in part by the functions of the liver, for example defending the body 
from bacteria and toxins. Sinusoidal endothelial cells and Kupffer cells 
form the first line of cells for bacteria and toxins delivered by the 
portal blood flow. When liver endothelial or Kupffer cells are 
stimulated, they release inflammatory, toxic and vasoactive mediators 
that modulate the vascular tone in hepatic microcirculation. 
Experimental reductions of Kupffer cells prior to the onset of septic 
shock prevented the occurrence of hepatocellular dysfunction and the 
upregulation of inflammatory cytokines (Koo et al. 1999). In the 
progression of sepsis, sinusoidal epithelial cells undergo structural and 
functional changes, which cause the leakage of albumin, plasma and 
inflammatory cells into the interstitium. In addition, epithelial cells 
lose their normal anticoagulant state, causing leukocytes and platelets 
to adhere to endothelial cells (Croner et al. 2006). All these adverse 
events cause hepatic microvascular ischemia and dysfunction, leading 
to hepatocellular injury and failure.  
2.2.4 Hyperlactatemia and mitochondrial dysfunction in 
septic shock 
Hyperlactatemia during septic shock is often considered to be 
evidence of tissue hypoperfusion and hypoxemia (Mizock and Falk 
1992).  However, a significant quantity of lactate is produced from 
carbohydrate metabolism in the skeletal muscle, heart and brain in 
fully aerobic conditions (Brooks 1986). In hypoxic surroundings, the 
hydrolysis of ATP leads to an accumulation of H+ ions into the cells, 
causing acidosis. Under aerobic conditions, lactate is generated in a 
process linking the glycolytic ATP supply to the stimulation of Na+K+ -
ATPase. In this process, the H+ ions are recycled during glucose 
metabolism, and this aerobic procedure does not cause acidosis. 
Lately, there have been wide discussions about whether lactate release 
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in septic shock is indeed due to hypoxia or is merely an effect of 
aerobic glycolysis (Levy 2006, McCarter et al. 2002). The latter occurs 
not only in well-oxygenated skeletal muscle but also during 
hemorrhagic and septic shock and is closely linked to the stimulation 
of sarcolemmal Na+/K+ -ATPase under epinephrine stimulation 
(James et al. 1999).  
Na+/K+ -ATPase maintains Na+ and K+ concentration gradients 
and the cell membrane potential by actively pumping Na+ out and K+ 
into the cell. A resting muscle cell uses approximately 10% of its 
Na+/K+ -ATPase to maintain Na+ and K+ gradients. When muscle 
activity is higher, the reserves of Na+/K+ -ATPase are deployed, 
preserving the membrane sensibility (Nielsen and Clausen 1996).  The 
Na+/K+ -ATPase is stimulated by many factors, including insulin, 
epinephrine, corticosteroids and increased intracellular sodium 
(Clausen 2003). Endogenous epinephrine concentrations are typically 
elevated in trauma and septic and hemorrhagic shock patients 
(Benedict and Grahame-Smith 1978, Abbound et al. 2009). Levy et al. 
tested the hypothesis of epinephrine-induced hyperlactatemia in 14 
septic shock patients by collecting lactate and pyruvate from 
quadriceps muscles with microdialysis (Levy et al. 2005). Lactate and 
pyruvate concentrations were higher in the muscle than in arterial 
blood, suggesting that muscle could be a leading source of lactate 
formation as a result of aerobic glycolysis. In the intervention group, 
they used ouabain, a specific inhibitor of Na+/K+ -ATPase, which 
stopped the over production of muscle lactate and pyruvate. Another 
indirect proof for the participation of muscle Na+/K+ -ATPase in 
hyperlactatemia in trauma or septic patients is the prevalence of 
hypokalemia. More than 50% of the randomly selected trauma patients 
presented hypokalemia, and it is correlated with serum epinephrine 
levels (Vanek et al. 1994).  
Sepsis and septic shock are characterized by early vasodilatation 
and extravasation. Intravascular volume is depleted, which leads to a 
decreased preload and low cardiac output. If fluid therapy and other 
treatments for the maintenance of blood perfusion fail, it may lead to 
an oxygen supply-demand imbalance in several organs (Dyson et al. 
2007). Fluid resuscitation in early sepsis, which is discussed later, 
improves clinical outcomes. However, during established sepsis and 
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organ failure, the enhanced oxygen delivery with fluids and 
dobutamine seems to show no benefit; non-survivors do not have the 
ability to increase oxygen consumption, despite a seemingly adequate 
oxygen supply (Hayes et al. 1997). Since ATP production by 
mitochondrial oxidative phosphorylation accounts for more than 90% 
of total oxygen consumption, it seems that oxygen delivery-
consumption mismatch may be a sign of compromised mitochondrial 
function. Brealey et al. analyzed skeletal muscle ATP concentrations in 
critically ill septic patients (Brealey et al. 2002). They found that non-
survivors had significantly lower ATP concentrations, nitride oxide 
overproduction and antioxidant depletion than survivors.    
2.2.5 Bacterial translocation  
Bacterial translocation is a phenomenon in which bacteria or its 
products, such as endotoxins, enter the blood stream from the lumen 
of the gut. It is thought to be a motor of septic shock and in the 
development of MODS, and this theory of bacterial translocation has 
been supported by many studies (Naaber et al. 2000, Alexander et al. 
1990, Baker et al. 1988, Woodcock et al. 2001).  
Bacterial translocation may occur if the epithelial cells of the gut are 
injured. As discussed earlier, the sensitive microcirculation 
(countercurrent exchange) of the jejunal villi expose them to hypoxic 
injury. Ischemia-reperfusion injury releases oxygen-free radicals, 
which can cause direct mucosal injury and the secondary activation of 
polymorphonuclear neutrophils. Reperfusion with oxygen-rich blood 
then aggravates microvascular injury, cellular necrosis and apotosis by 
releasing cytokines (Balzan et al. 2007). Bacteria are thought to have 
two pathways of translocation: through enterocytes or using tight 
junctions. The access to systemic circulation also includes two routes: 
through the venous or lymphatic systems. However, in the study of 
Moore et al, only 2% of trauma patients had positive portal venous 
bacterial cultures within five days of follow-up, despite an eventual 
30% incidence of MODS (Moore et al. 1991). Lemaire et al. studied the 
endotoxin concentrations of the thoracic duct to evaluate if the 
lymphatic duct was the route of translocated bacteria in patients with 
MODS (Lamaire et al. 1999). They found low concentrations of 
endotoxins from the thoracic duct, supporting the theory of lymphatic 
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translocation, but the authors were skeptical that the lymphatic route 
was a major route of bacterial translocation. However, there is recent 
evidence that mesenteric lymph is indeed an essential route for gut-
derived toxic products causing MODS (Deich et al. 2006).  
2.2.6 Coagulation system in sepsis 
It is well known that severe infection commonly leads to the activation 
and disorder of the coagulation system. There is also solid evidence 
that coagulation increases inflammatory activity. Inflammation 
expresses intravascular tissue factor, enhances leukocyte adhesion 
molecules, and down-regulates the fibrinolytic and protein C 
anticoagulant pathways. This relationship is not only important in 
specific vascular diseases but also in the pathogenesis of microvascular 
failure in severe sepsis and in the development of MODS. 
Cytokines, such as IL-1, IL-6 TNF-α, are the main mediators of 
inflammation induced coagulation (van Deventer et al. 1990, 
Moermeester et al. 1995). Tissue factor, normally found in the 
adventitial layer of larger blood vessels, also possesses a central role in 
the initiation of inflammation-induced coagulation. When vascular 
integrity is disrupted, tissue factor comes into contact with blood and 
initiates the coagulation system by activating thrombin generation. In 
severe sepsis, tissue factor is stimulated by proinflammatory 
cytokines, which leads to the systemic activation of coagulation 
(Osterud et al. 2000). One of the main functions of thrombin is 
converting fibrinogen into fibrin. Among the other mechanisms, 
thrombin amplifies coagulation, and it is also one of the strongest 
activators of platelets (Levi and van der Poll 2005).   
Coagulant activity is normally regulated by antithrombin, the 
protein C system, and the tissue factor pathway. All these mechanisms 
can be impaired during inflammation. The powerful anticoagulant 
effect of protein C, normally activated by the endothelial cell 
membrane-associated thrombomodulin, is deteriorated when 
endothelial dysfunction occurs during inflammation (Esmon 2002). 
The role of activated protein C in the treatment of septic shock is 
discussed later in this review.  
A decreased number of platelets and their dysfunction is often seen 
in severe sepsis and septic shock (Lee et al. 1993). The platelet 
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activating factor (PAF) is a phospholipid-signaling molecule that plays 
a key role in transmitting signals to several hemostatic systems, 
including platelets. Injurious stimuli, either by trauma or infection, can 
activate the PAF signaling system, leading to the activation of acute 
inflammatory and thrombotic cascades (Zimmerman et al. 2002). In 
severe infections, the regulation system of PAF is often disorganized, 
leading to a pathological amplification of inflammation, thrombosis 
and platelet aggregation (Mathiak et al. 1997, Woth et al. 2010). This, in 
turn, may cause the impairment of microvascular perfusion, which is 
already seen in the early stages of sepsis (Spanos et al. 2010).  
Several specific PAF antagonists have been discovered, and their 
efficiency in animal studies has been demonstrated (Afroz et al. 1998). 
However, their effectiveness in clinical studies is less convincing. It 
seems that certain antagonists may reduce the incidence of MODS, but 
they have failed to prevent mortality in septic shock (Poeze et al. 2000, 
Suputtamongkol et al. 2000).    
2.2.7 Development of organ failures 
The concept of organ dysfunction syndrome, later named multiple 
organ dysfunction syndrome (MODS), was originally described by 
Ashbaugh et al. in the late 1960s and was specified by Baue a few 
years later (Ashbaugh et al. 1967, Baue 1970). During the last decades, 
our understanding of MODS has developed, and the present 
consensus is that there must be a wider variety of biological 
modulators that are the driving forces of MODS, not just uncontrolled 
systemic infection (Fry 2000).   
MODS is defined as a progressive dysfunction of two or more of 
the following organ systems: respiratory, renal, liver, central nervous 
system, coagulation or hemodynamic collapse. It is one of the leading 
causes of mortality in ICUs. Along with sepsis, MODS is responsible 
for more than 60% of deaths after severe trauma, 50% of deaths from 
pancreatitis, 30% of deaths after burn injury and is also common in 
ICU patients admitted after cardiac arrest (Mongardon et al. 2009).  
Several studies have shown organ failures without bacterial 
infection, such as in hemorrhagic shock (Heckbert et al. 1998) and 
trauma patients (Barie et al. 2009). Since MODS can occur without 
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sepsis (Goris et al. 1985), it is thought to be a potential consequence of 
any biological stress that activates systemic inflammation.  
There are probably several mediators that play roles in the 
development of MODS, and at least neutrophils, macrophages, 
endotoxins, cytokines and reactive oxygen species have been 
suggested (Maier 2000). MODS induces the diffuse activation of 
neutrophils throughout the body by a chemoattractant signal, such as 
IL-8. It attracts neutrophils to marginate in the vasculature, and 
adhesion molecules of neutrophils and endothelial cells cause 
neutrophilial adherence to the vascular wall. Additional adherence 
molecules induce migration through the endothelium and 
extravasation into the tissue (Albelda et al. 1994). Ischemia-reperfusion 
causes neutrophils to release oxidants and proteases, which leads to 
additional capillary leaks and vasodilatation. Neutrophils also have 
the capability to adhere to each other, forming microvascular 
thrombosis, tissue necrosis and the release of additional toxic 
substances.  
Macrophages are central to controlling the entire inflammatory 
response. They are able to produce numerous inflammatory 
mediators, such as TNF, IL-1 and other proinflammatory cytokines. 
These, in turn, attract additional inflammatory cell types, amplifying 
the inflammation cascade.  
Endotoxin is a lipopolysaccaride that is found on the wall of gram-
negative bacteria. If a patient with sepsis caused by gram-negative 
bacteria is treated with antibiotics that dissolve the bacterial wall, it 
may cause the extensive shedding of endotoxins (Eng et al. 1993) and 
increase the production of proinflammatory mediators, contributing to 
the severity of the sepsis. 
In addition to the several other homeostatic systems, cytokines play 
a pivotal role in the development of MODS. The cytokine cascade is 
very complex, and strategies of a single cytokine blockade in order to 
prevent MODS or reduce the mortality rate have been unsuccessful 
(Cohen and Carlet 1996, Abraham et al. 1995).   
Oxidants are important causes of extracellular injury and signal 
transducers of inflammatory stimuli. The role of antioxidants in 
preventing organ damage in the animal models has been successfully 
demonstrated (Rhee et al. 1991), but they have not proven effective in 
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clinical studies. N-acetylcysteine (NAC) scavenges hydroxyl radicals, 
and it has a protecting effect in neutrophilial-induced alveolitis in 
endotoxemic rats (Blackwell et al. 1996). NAC seems to have some 
beneficial effects in the clinical setting by reducing the need of 
mechanical ventilation and improving the oxygenation index. 
However, there was no significant improvement in mortality rates 
(Suter et al. 1994).  
Some data suggest that there is a critical time window for some 
therapies in the prevention of MODS. If this time period is passed, 
interventions fail probably because the cellular processes become 
irreversible (Jepsen et al. 1992).  
2.2.8 Treatment of sepsis and septic shock 
In sepsis and septic shock, rapid initiation of treatment seems to be 
critical. Septic patients should be quickly identified, and the beginning 
of the treatment should not be delayed. There may be clinically 
significant delays in initiating proper treatment with patients who are 
in septic shock in general wards, and even such delays seem to 
increase mortality (Lundberg et al. 1998). Simple methods to recognize 
the patients who are in danger of septic shock have been developed 
(Thiel et al. 2010). Early goal-directed therapy for rapid hemodynamic 
and oxygen-delivery maintenance has been shown to decrease 
mortality in cases of septic shock (Rivers et al. 2001). Prompt 
hemodynamic resuscitation, restoration of tissue oxygenation, rapid 
administration of broad-spectrum antibiotic therapy and infection 
source control are the cornerstones of successful sepsis management 
(Russel 2008).  
In 2004, the Surviving Sepsis Campaign created international 
guidelines for the management of severe sepsis and septic shock 
(Dellinger et al. 2004); these guidelines were updated in 2008 
(Dellinger et al. 2008). The effectiveness of these guidelines was 
evaluated and it was associated with sustained quality improvement 
in sepsis care (Levy et al. 2010). 
2.2.8.1 Source Control 
Along with early fluid resuscitation and antimicrobial medication, 
source control is considered one of the most important steps in the 
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treatment of septic shock, yet extensive scientific research on the 
subject is lacking. The term ‘source control’ means eliminating the 
source of infection, controlling contamination, and restoring normal 
anatomy and organ function. There are several ways to achieve source 
control, such as the drainage of abscesses; the debridement of necrotic 
tissues or foreign material; the decompression of the abdominal cavity; 
and finally, the restoration of normal anatomy. Which procedure is 
chosen must be considered on a case-by-case basis depending on the 
source of infection and the severity of the illness. De Weale proposes 
three urgency levels for source control. 1) The patient has progressive, 
life-threatening disease, such as necrotizing soft tissue infection or 
intra-abdominal infection with deteriorating organ dysfunction – 
emergent source control should be carried out within 1-2 hours. 2) The 
vast majority of surgical infections can be classified in the category of 
urgent source control, such as patients with localized peritonitis, 
pleural empyema or postoperative wound abscess. However, 
resuscitation should be started immediately, and the source control 
should take place as soon as possible, preferably within three hours. 3) 
In some patients, delayed source control is appropriate. For example, 
for patients with infected pancreatic necrosis, source control may be 
safer after demarcation of the infection (De Waele 2010).          
2.2.8.2  Antibiotics 
The Surviving Sepsis Campaign put forth three important 
recommendations concerning antimicrobial therapy: 1) intravenous 
antibiotics should be initiated within the first hour after severe sepsis 
or septic shock are recognized; 2) treatment should begin with broad-
spectrum agents that can penetrate into the presumed site of infection; 
and 3) daily reassessment of the antimicrobial regimen should be done 
to optimize efficacy and resistance, avoid toxicity and minimize costs. 
In addition, it should be remembered that drug pharmacokinetics in 
critically ill patients is often unpredictable, and under- and 
overexposures of drug concentrations may occur if each patient’s 
clinical condition is not carefully assessed (Pea et al. 2005).  
The benefit of the early antimicrobial treatment of septic patients 
was endorsed by the sub-analysis of the FINNSEPSIS study. Hospital 
and one-year mortality were markedly higher if early resuscitation 
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failed (for example, delayed antimicrobial treatment, insufficient 
hemodynamic support [SAPm < 65 mmHg, CVP < 8 mmHg], or 
improper tissue oxygen supply [SvO2 < 70%]) compared to patients 
with successful early treatment (42% and 59% vs. 24% and 36%, 
respectively). The failure of the early antimicrobial treatment was 
shown to be the most important individual factor in predicting higher 
mortality (Varpula et al. 2007).   
2.2.8.3  Volume resuscitation 
Hemodynamic stabilization can be divided into two categories: fluid 
resuscitation and the use of vasoactive drugs. Fluid resuscitation 
should be started as soon as possible and should be administrated 
according to fluid challenge techniques. Attention should be given to 
the quantity, rather than the quality, of fluids. There is no evidence 
favoring one type of fluid over another; fluid resuscitation can be 
performed with crystalloids or colloids, or both.  During fluid 
resuscitation, clinical assessment should be done repeatedly. One 
should focus on reaching adequate SAPm (>65-70 mmHg), heart rate 
(<110/min) and CVP  (< 15mmHg). Red blood cells should be given if 
the haematocrit drops under 0.30 or Hb < 70 g/l. Whether this 
transfusion threshold should be higher in certain patient groups, such 
as those with ischemic heart disease, is still under debate (Vincent et 
al. 2008, Rivers et al. 2001).  
However, fluid administration after the initial fluid resuscitation 
changes in the ICU. Despite their hypotension, lactic asidosis, or 
persisting organ dysfunction, it is common that septic patients are not 
hypovolemic. In contrast, patients are often hypervolemic, and 
excessive fluid challenges may only lead to increased extravasation, 
causing edema in the lungs and other tissues. It has been proposed 
that fluid infusions should be kept to a minimum, and the volume 
balance should be assessed frequently. Assessment of the fluid balance 
according to CVP and PAOP may not be reliable for mechanically 
ventilated patients (Durairaj and Schmidt 2008). Instead, volume 
estimation with pulse pressure variation (PPV) seems to have a strong 
correlation with detecting the patients who might benefit from fluid 
challenge (Michard et al. 2000).    
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2.2.8.4  Vasoactive therapy 
In severe sepsis and septic shock, the use of vasoactive therapy is often 
essential. If there are signs of systemic or regional hypoperfusion that 
does not react to volume resuscitation, vasoactive therapy should be 
initiated promptly. The goal of vasoactive therapy is to restore 
adequate tissue perfusion and cellular metabolism (Hollenberg 2009). 
Vasoactive agents can be divided into two categories, vasopressors to 
increase blood pressure and inotropes to increase systemic blood flow 
and oxygen delivery. The choice of which vasopressor to use is 
discussed later in this review.  
2.2.8.5 Glucose control 
In sepsis, massive releases of pro- and anti-inflammatory cytokines 
cause several metabolic changes – hyperglycemia is one of the most 
important. Van den Berghe et al. demonstrated that tight glucose 
control (a blood glucose level between 4.4 - 6.1 mmol/L) had a 
significant reduction in overall mortality, from 8 % to 4.6 %, in ICU 
patients. Deaths due to multiple organ failure with septic focus 
decreased most in the intensive glucose control group. There were also 
significant reductions in bloodstream infections, acute renal failure, 
red-cell transfusions, critical-illness polyneuropathy, the need for 
mechanical ventilation, and intensive care (van den Berghe et al. 2001). 
However, later studies have questioned tight glucose control in septic 
patients because of the increased risk of severe hypoglycemia and 
complications thereof. The recent, prospective, randomized NICE-
SUGAR study compared the mortality of intensive glucose control 
(blood glucose 4.5 - 6.0 mmol/L) and conventional glucose control 
groups (blood glucose < 10.0 mmol/L). The mortality was significantly 
higher in the intensive glucose control group (Finfer et al. 2009). The 
proper blood glucose level of a septic patient is under discussion, but 
until further studies are conducted, it may be reasonable to avoid too-
tight glucose control.  
2.2.8.6 Activated protein C and corticosteroids 
Activated protein C (APC) is an endogenous protein that promotes 
fibrinolysis and inhibits thrombosis and inflammation. In severe 
sepsis, its effectiveness may be downregulated by inflammatory 
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cytokines and oxidants (Esmon 2003). This may lead to unfavorable 
thrombosis formation, tissue hypoperfusion and MODS.  
APC  administration  prevented  adverse  coagulopathic events  and  
the  lethal  effects  of  e. coli  in the experimental  model (Taylor  et al.  
1987).  Bernard et al. studied the efficacy and safety of drotrecogin alfa 
activated (recombinant human activated protein C) in septic shock 
patients (Bernard et al. 2001). Protein C deficiency was present in 
87.6% of the patients, and the plasma D-dimer level was elevated in 
almost all patients. The twenty-eight day mortality rate in the placebo 
group was 30.8% and 24.7% in the treatment group, representing a 
reduction in the relative risk of death of 19.4%. The most feared 
complication associated with APC, serious bleeding, was modestly 
higher in the APC group than in the placebo group (3.5% vs 2.0%, 
p=0.06, respectively). Also, other authors have concluded that the early 
treatment of septic shock with APC may reduce hospital mortality 
(Lindenauer et al. 2010). Ensuring the safety and efficacy of APC still 
requires more evidence.      
In sepsis, the hypothalamic-pituitary-adrenal axis is disturbed, 
cortisol response is suppressed, and peripheral tissue may become 
resistant to glucocorticoids (Chrousos 1995, Prigent et al. 2004). The 
benefit of corticosteroids is controversial in the treatment of septic 
shock (Sprung et al. 2008, Groeneveld et al. 2008). There is some 
evidence that low-dose corticosteroid treatment could have beneficial 
effects on short-term mortality (Annane et al. 2009).  
 
2.3  BRAIN DEATH  
2.3.1 Hemodynamic changes during brain death 
If intra-cranial pressure increases, for example, due to major ischemia 
or cerebral bleeding, blood perfusion to the brain deteriorates and the 
brain becomes ischemic. While ischemia proceeds to the pons of the 
brain, it results in both vagal and sympathetic stimulation, which is 
characterized by bradycardia and hypertension, also known as the 
Cushing reflex. When the ischemia reaches the distal medulla 
oblongata and the vagal motor nucleus, strong sympathetic 
stimulation (a sympathetic storm) takes place; the hemodynamic 
pattern is characterized by strong tachycardia and hypertension. 
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Further progression of brain herniation leads to spinal cord ischemia, 
gradual loss of all sympathetic tone, and eventually, hypotension and 
cardiovascular collapse (Bugge 2009). The massive catecholamine 
release during brain death causes myocardial injury and is probably 
the main reason for the subsequent loss of cardiac function (Berman et 
al. 2010).  
2.3.2 Hemodynamic management in brain death organ 
donors 
Vasopressors are almost always needed to support hemodynamics 
and blood perfusion in brain death organ donors (Salim 2006). The 
most commonly recommended vasoactive drugs for this situation are 
dopamine, epinephrine, norepinephrine and vasopressin (Schnuelle et 
al. 2009, Mascia et al. 2009, Kutsogiannis et al. 2006). The 
Transplantation Committee of The American College of Cardiology 
recommends vasopressin as the primary vasoactive drug in the 
treatment of hemodynamics and diabetes insipidus on brain-dead 
heart donors (Hunt et al. 1996). Vasopressin seems to decrease 
splanchnic and especially small gut blood perfusion during 
vasodilatory shock (Nygren et al. 2009). However, the effects of low 
dose vasopressin are controversial (Asfar et al. 2008), and it has been 
suggested that it may even improve splanchnic circulation in 
experimental endotoxin shock (Asfar et al. 2003). 
2.4  SHORT GUT SYNDROME 
Whether congenital or acquired (through gut ischemia, trauma, tumor, 
etc.), short gut syndrome often leads to long-term parenteral nutrition. 
This, in turn, may lead to several complications such as parenteral 
nutrition-associated cholestasis, liver disease, sepsis, central venous 
catheter infections or death (Ekema et al. 2009). Mortality from short 
gut syndrome and its complications may be as high as 47 % 
(Schalamon et al. 2003). Because of several disadvantages and 
complications associated with parenteral nutrition, small gut 
transplantations from living relatives have been achieved in recent 
years (Wang et al. 2005, Wada et al. 2005). However, living relative 
donors are rarely eligible, and therefore, bowel transplantations from 
brain-dead organ donors have also been successful (Lauro et al. 2007).  
27 
 
 
 
2.5  VASOACTIVE AGENTS 
Septic shock involves several pathological hemodynamic alterations 
including vasodilation, extravasation, relative and absolute 
hypovolemia, myocardial dysfunction, and altered regional and 
microvascular blood flow redistribution. In septic shock, the 
autoregulation of organ blood flow is disturbed, leading to a linear 
relationship between organ blood flow and perfusion pressure (Sladen 
and Landry 2000). One of the primary goals in the treatment of septic 
shock is to restore effective tissue perfusion. If volume resuscitation 
fails to restore adequate blood perfusion, vasopressors and inotropes 
are often needed. Vasopressors and their primapry receptros and 
actions are presented in Table 2.   
  
  
 
 
Table 2. Receptors and actions of vasoactive agents.  
 
2.5.1 Catecholamines 
The catecholamines have played the essential role of increasing 
systemic and regional blood perfusion in cases of septic shock. They 
can be divided into inotropes or vasopressors, some having both 
properties. Catecholamines act via α- or β-receptors, the former mainly 
providing vasoconstriction, and the latter mainly increasing cardiac 
performance (Leone and Martin 2008).  
Norepinephrine is frequently used as a first line vasopressor in the 
hemodynamic management of septic shock. It has a strong α-
adrenergic effect, and also weaker β-adrenergic effects. 
Norepinephrine increases arterial blood pressure and may have 
beneficial effects on renal (Albanèse et al. 2004, Desjars et al. 1989) and 
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mesenteric circulation (Sennoun et al. 2007) in septic shock. It also 
seems to increase tissue oxygenation in dopamine-resistant septic 
shock without apparent adverse effects (Martin et al. 1993). The effects 
of norepinephrine on splanchnic circulation are conflicting: in the 
clinical study by Marik and Mohedin, splanchnic circulation seemed to 
be preserved in norepinephrine-treated septic shock (Marik and 
Mohedin 1994); this is supported by our own experimental study 
(Martikainen et al. 2003). On the other hand, according to Krejci et al, 
norepinephrine was associated with decreased mesenteric blood flow 
and jejunal mucosal microcirculation (Krejci et al. 2006).    
Epinephrine is a potent α- and β-adrenergic agent that increases 
both vascular resistance and cardiac index (Moran et al. 1993). One of 
its indications is to increase arterial blood pressure in patients who are 
resistant to other catecholamines. The main concern related to the use 
of epinephrine in septic shock is its potential to decrease splanchnic 
circulation and oxygen delivery (Meier-Hellmann et al. 1997). 
Hyperlactatemia is often associated with the use of epinephrine (Levy 
et al. 1997). However, it is uncertain whether this is due to tissue 
hypoperfusion or is merely a sign of aerobic glycolysis. Despite the 
wide range of possible deleterious effects of epinephrine, according to 
Annane et al., there was no significant difference in mortality between 
the uses of epinephrine versus norepinephrine in dobutamine-treated 
septic shock patients (Annane et al. 2007).  
Dopamine, a precursor of norepinephrine, has β-adrenergic effects 
in lower dosages and α-adrenergic effects in higher dosages; in low 
dosages is has dopaminergic effects as well. Dopamine may increase 
renal blood flow, thus increasing diuresis, but this may be the result of 
increased cardiac index (Juste et al. 1998). The kidney protective effect 
of dopamine is controversial, as it has not been shown to decrease the 
need for dialysis (Marik 2002).  
Dopexamine is a synthetic analogue of dopamine that induces 
systemic vasodilatation through the stimulation of β2 adrenoceptors 
and peripheral DA1 and DA2 receptors. It also has weak inotropic 
properties that are active through the stimulation of β1 adrenoceptors. 
Dopexamine has been shown to restore mesenteric and celiac 
hemodynamics in hemorrhagic shock in canines (Chintala et al. 1993), 
and pre-treatment of ischemia-reperfusion organ injury with 
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dopexamine may prevent lipid peroxidation induced by oxygen free 
radicals (Jacinto et al. 1997). Dopexamine is also associated with 
increasing splanchnic blood flow with septic patients needing 
vasopressor support, however, it does not influence hepato-splanchnic 
metabolism (Kiefer et al. 2001). In another study by Kiefer et al., 
dopexamine increased cardiac output and absolute splanchnic blood 
flow, but fractional splanchnic perfusion decreased, and neither global 
or regional oxygen consumption (VO2) nor pCO2 gradients were 
significantly affected (Kiefer et al. 2000) .  
Myocardial dysfunction is often seen in septic shock patients. Its 
pathophysiology remains unclear, but it is associated with the 
stimulation of the immune system and the release of proinflammatory 
mediators and microvascular dysfunction (Hunter and Doddi 2010). 
For inotropic support in septic shock, dobutamine is considered the 
gold standard. It is usually used not as a sole vasoactive agent, but in 
combination with some vasoconstrictor. It may improve gastric 
perfusion when combined with norpepinephrine (Duranteau et al. 
1999, Zhou et al. 2002), and may reverse the deleterious effects of 
vasopressin in septic shock (Morelli et al. 2008). 
2.5.2 Vasopressin 
Vasopressin (antidiuretic hormone) is synthetized in the 
hypothalamus and stored in the posterior pituitary gland. In a normal 
physiological state it regulates blood pressure by being released from 
the pituitary gland in reaction to increased blood osmolality or 
decreased blood pressure (Bourque 1998). The effects of vasopressin 
are mediated via three receptors: V1, V2, and V3. V1 –receptors are 
located on the systemic, splanchnic, renal and coronary vascular 
smooth muscles. V2 –receptors are located in the kidney, and they 
mediate the antidiuretic actions of vasopressin. V3 –receptors are found 
in the anterior pituitary gland; their action is correlated with the 
secretion of adrenocorticotrophic hormone (Barret et al. 2007). In 
addition, vasopressin has a high affinity for oxytocin receptors, and is 
therefore also able to cause vasodilatation via nitric oxide release.  
Vasopressin levels increase in early sepsis, but decrease as sepsis 
progresses (Sharshar et al. 2003) and after traumatic brain injury 
(Behan et al. 2008). This may be explained by the depletion of 
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vasopressin stores in the neurohypophysis (Sharshar et al. 2002). 
Therefore, exogenous vasopressin (or its synthetic analogues) has been 
used in the treatment of catecholamine–resistant septic shock and in 
the hemodynamic stabilization after brain death.  
Even though it seems to effectively maintain systemic blood 
pressure, the safety of vasopressin is under active discussion. The use 
of vasopressin is associated with decreased cardiac output (Holmes et 
al. 2001), decreased systemic oxygen delivery and mixed-venous 
oxygen saturation (Ertmer et al. 2008), increased liver enzymes and 
bilirubin, and a decreased platelet count (Luckner et al. 2005). Special 
concern is caused by a possible decrease in splanchnic perfusion 
(Nygren et al. 2009), even though opposite results have been published 
(Klinzing et al. 2003).   
A recent, prospective, double-blinded, multi-center VASST study 
found no difference in overall 28-day mortality between 
norepinephrine-   and    vasopressin-treated    (39.3% and 35.4%, 
respectively; P=0.26) septic shock patients. Also, the incidence of 
serious adverse effects and organ dysfunction were similar. 
Additionally, open-labeled norepinephrine infusion was lower in the 
vasopressin group in order to maintain systemic blood pressure. The 
authors conducted sub-group analysis of less severe sepsis, and 28-day 
mortality seemed to be lower among vasopressin-treated patients than 
those treated with norepinephrine, even though absolute statistical 
significance was lacking (Russel et al. 2008).  
Even though the authors in the VASST study could not show 
undisputed evidence of the beneficial effects of vasopressin, they 
demonstrated trends favoring vasopressin over norepinephrine, and 
the adverse effects they observed were similar. Therefore, vasopressin 
cannot be rejected in the treatment of septic shock, and more 
investigation is needed.  
2.5.3 Levosimendan 
Levosimendan is a calcium sensitizer that increases heart contractility. 
So far, it has only been indicated in the treatment of sudden 
deterioration from chronic myocardial insufficiency. Since septic shock 
is often accompanied by myocardial dysfunction (Hunter and Doddi 
2010), levosimendan is an attractive choice for the treatment of 
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hypoperfusion in the septic shock. It has shown to have beneficial 
effects on systemic and portal blood flow in animal studies (García-
Septien et al. 2010). However, it seems not to improve the total 
splanchnic perfusion on experimental septic shock (Cunha-Goncalves 
et al. 2009). Few clinical studies have so far investigated its use in 
septic shock. The relatively small study by Alhashemi et al (n=42) 
indicated a minor decrease in systemic lactatemia associated with the 
use of levosimendan, whereas central venous oxygen saturation did 
not change compared to the use of dobutamine (Alhasheimi et al. 
2009). However, there is some evidence that levosimendan may be 
superior to dobutamine in sepsis-induced myocardial dysfunction, but 
further studies are needed (Pinto et al. 2008). The pharmacokinetic 
properties of levosimendan differ from the other vasoactive agents 
used in the treatment of septic shock: the half-life of elimination is 
approximately one hour, but the half-life of the active metabolites is up 
to 80 hours, and the hemodynamic effects may last as long as seven to 
nine days. Therefore, levosimendan lacks the rapid adjustability of the 
catecholamines and vasopressin, which may cause trouble in the 
treatment of the hemodynamics of a septic patient. 
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3 Aims of the present study 
 
In the present series of experiments, our main focus was to gain a 
better understanding of the effects of different vasoactive agents on 
the systemic and regional hemodynamic and metabolic changes in 
endotoxemic shock and after brain death.  
 
Our special focuses were: 
 
• Does dopexamine cause blood flow distribution or metabolic 
changes within the splanchnic area during prolonged endotoxin 
shock? 
 
• Does vasopressin compromise systemic or splanchnic blood flow 
in experimental endotoxin shock?  
 
• Does dobutamine prevent the systemic and splanchnic 
hypoperfusion and adverse metabolic changes caused by 
vasopressin?  
 
• Are arterial hyperlactatemia and acidosis caused by epinephrine 
due to splanchnic tissue hypoperfusion?  
 
• Is norepinephrine effective in restoring systemic blood perfusion 
in severe endotoxin shock, and does it have harmful effects on 
splanchnic perfusion or metabolism?  
 
• Is low-dose vasopressin effective and safe compared to dopamine 
concerning the vitality of the small gut after brain death? 
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4 Materials and Methods 
 
These experiments were approved by the Institutional Animal Care 
and Use Committee of the University on Kuopio and The National 
Animal Ethics Committee of Finland.  
 
4.1  ANIMALS  
Finnish landrace pigs were used in each of the five experiments. 
Publications I and II each consisted of 21 animals, publications III and 
IV of 12 animals each, and publication V of 15 animals, for a total of 81 
animals. The animals were made to fast for 24 to 48 hours prior the 
experiment, but had free access to water. In the endotoxin shock 
model, the gastro-intestinal tract was emptied with an osmotic 
laxative. Animals in the control groups were anesthetized, operated 
and monitored as animals in the intervention groups. However, after 
stabilization, the endotoxin infusion was not started, but the 
hemodynamic monitoring and blood sample collection were 
performed identically. At the end of the experiments, the animals were 
euthanized via intra venous injection of magnesium sulphate.  
 
4.2  EXPERIMENTAL ENDOTOXEMIC SHOCK 
4.2.1 Anesthesia and ventilation 
In studies I and II, the animals were sedated with intramuscular 
injections of atropine 0.05 mg/kg and azaperone 8 mg/kg. In studies III 
and IV, sedation was performed with atropine 0.05 mg/kg, ketamine 8-
10 mg/kg and xylazine 2 mg/kg.  
Anesthesia was induced with intravenous sodium thiopental 5-15 
mg/kg. In addition, ketamine 250 mg was given in experiment I. 
Anesthesia was maintained with the continuous infusion of thiopental 
5 mg/kg/h. Analgesia was maintained with the continuous infusion of 
fentanyl 30 μg/kg/h during the surgical manipulation, after which the 
infusion was reduced to 5 μg/kg/h.  
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The airway was secured in each animal with a tracheotomy. The 
ventilation was performed with a volume-controlled mode ventilator 
(Servo 900E, Siemens Elema, Sweden), adjusting the tidal volume to 
10-15 ml/kg. Ventilation was adjusted to maintain normocapnia 
(PaCO2 4.5-5.5). FiO2 was adjusted in order to keep the arterial partial 
pressure of oxygen above 13.3 kPa. Positive end expiratory pressure 
(PEEP) was maintained between 5-8 cmH2O throughout the 
experiments. The inspiratory plateau pressure was maintained below 
25 cmH2O.  
4.2.2 Animal preparation 
Full sterility was maintained throughout the surgical manipulation. 
For each animal, the femoral artery was cannulated for measuring 
arterial blood pressure and collecting blood samples. A pulmonary 
artery catheter (Arrow, Arrow International, Inc., Reading, USA) and a 
hepatic vein catheter (MPA2 Angiographic catheter, Boston Scientific, 
Maple Grove, MA) were inserted through the right jugular or 
subclavian vein. After the full midline laparotomy, a catheter to the 
urine bladder was inserted. After visualizon of the portal vein, hepatic 
and superior mesenteric arteries and celiac trunk, ultrasound transit 
time flow probes (Transonic Systems Inc, Ithaca, NY) were inserted 
around the vessel. In addition, a flow probe was inserted around the 
descending aorta above diaphragm in experiment I. Colonic, 
mesenteric, gastric, and portal veins were cannulated to collect 
regional blood samples. Tonometers with microdialysis catheters were 
inserted into the colon, jejunum and stomach in experiments I and II, 
and to the surface of colon and/or jejunum in the experiments III and 
IV in order to collect mucosal or intraperitoneal lactate, pyruvate, 
glucose, and glycerol. A detailed description of the microdialysis 
manufactured in our own laboratory is in the original publication 
(Tenhunen et al. 1999).  
4.2.3 Fluid management  
For maintenance fluid therapy, saline 0.9% 5ml/kg/h was infused 
throughout the experiments. If systemic arterial blood pressure 
decreased abruptly, fluid challenges of 50-200ml were given. If 
pulmonary artery occlusion pressure (PAOP) fell below 5 cmH2O, 
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fluid resuscitation with Ringer’s acetate and hydroxyethyl starch 1:1 
was given. Central venous pressure (CVP) was not allowed to increase 
above 16 mmHg. Blood glucose was maintained with necessary 
infusions of a glucose solution of 30% or 50%.    
4.2.4 Hemodynamic monitoring 
Systemic and pulmonary arterial, hepatic, and portal vein pressures 
were recorded with quartz pressure transducers and displayed 
continuously on a multimodular monitor and recorder (CS3, Datex-
Ohmeda Instrumentarium, Helsinki, Finland). Automated data 
filtering (2-min median) was used when collecting the continuous 
variables (Deio Instrumentarium, Helsinki, Finland). Heart rate was 
measured with an electrocardiogram. PAOP was measured hourly. 
Cardiac output (CO) was measured using the thermodilution 
technique (mean value of three measurements) with room temperature 
saline injectants of 5 ml. Regional blood flows were measured with 
ultrasonic, transit-time flow probes (Transonic Systems, Ithaca, NY). 
Signals were recorded with flow meters (Flowmeters T108 and T208; 
Transonic Systems, Ithaca, NY), and the flow data were stored with 
computer software (Windaq; DATAQ instruments, Akron, OH). In 
vivo zero-flow signals were recorded at the end of each experiment. 
 
4.3 EXPERIMENTAL BRAIN DEATH MODEL 
Our endotoxin shock model and brain death model have several 
similarities and some differences. The latter are discussed in this 
chapter.   
4.3.1 Anesthesia and ventilation 
Sedation was performed with the intramuscular injection of 
medetomidine (Domitor Vet ® 1 mg/ml) 50 μg/kg, ketamine (Ketalar ® 
50 mg/ml) 10 mg/kg, and midazolam (Dormicum ® 1 mg/ml) 2 mg.  
Anesthesia was induced with propofol 3 mg/kg and maintained with 
propofol 1 mg/kg/h. Animals were orally intubated instead of using a 
tracheotomy. Anesthesia and analgesia were discontinued after the 
induction of brain death. Ventilation was performed similarly in 
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studies I-IV, but the tidal volume was reduced to 6-10 ml/kg according 
to the latest recommendations.  
4.3.2 Animal preparation 
The systemic and pulmonary artery catheters were inserted similarly 
in experiments I-IV. After the laparotomy, only the celiac trunk and 
superior mesenteric arteries were dissected free for flow probes. A 
commercial microdialysis capillary (CMA20, CMA Microdialysis, 5 
Stockholm, Sweden) was inserted inside the jejunal wall for 
intramucosal lactate, pyruvate, glucose, and glycerol measurements. 
The scalp was prepared from the left temporal area and a 10-mm hole 
was drilled into the scull. A catheter with an empty 50-ml balloon was 
inserted through the hole into the epidural space. 
4.3.3 Hemodynamic monitoring 
Hemodynamic monitoring, blood flow measurements and fluid 
management were maintained consistently in studies I-IV, with the 
exception that hydroxyethyl starch was replaced with 4 % gelatin 
(Gelofusine B. Braun Medical Oy, Germany).  
 
4.4 EXPERIMENT PROTOCOLS 
4.4.1 Endotoxemic shock models 
4.4.1.1  Dopexamine 
The animals were stabilized for 8-10 hours, after which they were 
randomized, using sealed envelopes, into three groups: ETX (n=7) with 
E. coli endotoxin infusion, DOPE (n=7) with E. coli endotoxin, and 
dopexamine infusion and controls (n=7). Baseline samples were 
collected, and if selected for group 1 or 2, an E. coli endotoxin 
(lipopolysaccharide 0111:B4, Difco Laboratories, Detroit, MI) infusion 
was started (20 μg/ml in glucose 5%) at a rate of 0.5 μg/kg/h. After 2-4 
h, the infusion rate was stepwise doubled (every 45-60 min) to induce 
systemic hypotension. An incremental dosage of endotoxin was 
limited by not allowing the mean pulmonary arterial pressure to 
exceed 40 mmHg. A dopexamine infusion was started after pulmonary 
hypertension occurred and was followed by an abrupt decrease in 
37 
 
 
 
cardiac output. We aimed to increase cardiac output to baseline or 
higher and adjusted the dopexamine infusion accordingly. When 
cardiac output exceeded baseline, the dopexamine infusion was 
continued at a fixed rate until the end of the experiment. 
Regional blood samples were taken at baseline and at 4, 8, 10, 12 
and 14 h. These samples were analysed for haemoglobin 
(Hemoxymeter OSM3, Radiometer, Copenhagen, Denmark), blood 
gases (Radiometer, Copenhagen, Denmark), lactate and pyruvate. In 
addition, samples for IL-1b and IL-6 were taken from the femoral 
artery. Arterial samples for endotoxin concentration measurements 
were taken at baseline and after the experiment. Microdialysis samples 
were collected in 30 min fractions throughout the experiment and 
microdialysate lactate was analysed within 5 min of fraction collection. 
Gastric, jejunal and colonic mucosal partial pressures of carbon 
dioxide were measured with a semiautomatic gas analyser (Tonocap®, 
Datex-Ohmeda, Helsinki, Finland) every 10 min throughout the 
experiment. The study flow chart is presented in Figure 3. 
 
 
Figure 3. Study flow chart of experiment I.   
4.4.1.2  Vasopressin vs. norepinephrine 
Animals were stabilized for 8–10 h, and were randomized into one of 
the following groups: Group 1 = E. coli endotoxin infusion (ETX; n = 6), 
Group 2 = endotoxin and vasopressin (VASO; n = 6), Group 3 = 
2h  2h  2h  
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endotoxin and norepinephrine (NOR; n = 6), or Group 4 = time 
controls (Control; n = 3). If randomized into groups 1-3, E. coli 
endotoxin infusion was started at the rate of 0.25 μg/kg/h, and after 1–
3 h, the infusion rate was doubled stepwise to achieve hypotension 
(SAPm < 60mmHg). Hypotensive, hyperdynamic shock was achieved 
within 10–18 h of the initiation of the endotoxin infusion. When the 
shock was achieved in groups 1 or 2, vasopressin (Pitressin®, Parke-
Davis, Karlsruhe, Germany) or norepinephrine (Levophed®, S.A. 
ABBOT NV, Belgium) was started and adjusted for 4 h, aiming for 
SAPm > 70 mmHg. The initial infusion rates for vasopressin and 
norepinephrine were 0.04 IU/min and 8 μg/min, respectively. The only 
vasoactive drug allowed was a bolus injection of epinephrine (0.02 
mg), in case of hemodynamic collapse (SAPm < 60 mmHg and 
pulmonary artery pressure > 50 mmHg), in the early (<2 h) stage of 
endotoxin infusion. Arterial blood samples were drawn hourly for 
hemoglobin, arterial blood gases, glucose, and lactate measurements. 
Colonic, mesenteric, portal, hepatic, gastric, and mixed venous blood 
samples were collected at baseline and at 0, 2, 3, and 4 h of vasopressor 
infusions (shock 0–4 h), and hemoglobin concentration, blood gases, 
and lactate concentrations were analyzed. Arterial plasma endotoxin, 
interleukin (IL)-1β, and IL-6 concentrations were measured at baseline 
and at the end of the experiment to verify the induction of the 
inflammatory response in this experimental model. The microdialysis 
samples were collected continuously over 30 min and analyzed within 
5 min (YSI 2300 Stat Plus, Yellow Springs Instruments Co Inc., Yellow 
Springs, OH). A gastrointestinal tonometer was used to measure the 
mucosal partial tension of carbon dioxide. A semiautomated gas 
analyzer was used every 10 min throughout the experiment. The study 
flow chart is presented in Figure 4.  
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Figure 4. Study flow chart of experiment II. 
4.4.1.3  Vasopressin vs. vasopressin and dobutamine 
The study protocol was quite similar to that of the previous 
experiment. There were two intervention groups, vasopressin (VASO; 
n = 6), and vasopressin and dobutamine (DOBU; n = 6). Hypotensive 
shock (SAPm < 60 mmHg) was achieved with prolonged endotoxin 
infusion (15-18h), and vasopressin was started and adjusted in both 
groups, aiming for MAP > 70mmHg. In the DOBU group, cardiac 
output was measured after 30 min. Dobutamine infusion (Dobutrex ®, 
Lilly Pharma Fertigung und Distribution GmbH & CO. KG, Giessen, 
Germany) was started with the aim of preventing a decrease in 
systemic blood flow from Shock 0 h-values (before vasopressin 
infusion). 
Arterial blood samples were drawn hourly for hemoglobin, arterial 
blood gases and glucose measurements. Arterial, colonic, mesenteric, 
portal, hepatic, gastric and mixed venous blood samples were 
collected at baseline and at 0, 2, 3 and 4 h of vasopressor infusions 
(shock 0 h — shock 4 h). Haemoglobin concentration, blood gases 
(ABL 520, Radiometer, Copenhagen, Denmark), lactate (YSI 2300 Stat 
Plus, Yellow Springs Instruments Co. Inc., Yellow Springs, OH) and 
pyruvate (SIGMAS UV-706 kit, Sigma Diagnostics, St. Louis, MO) 
concentrations were analyzed. Dialysate was collected for 30 min prior 
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to the endotoxin infusion, prior to the vasopressin infusion, and at the 
end of the experiment. Lactate concentrations were analyzed within 15 
min. The study flow chart is presented in Figure 5. 
 
 
Figure 5. Study flow chart of experiment III.  
4.4.1.4  Norepinephrine vs. epinephrine 
After instrumentation, the animals were stabilized for 6 h and 
randomized into epinephrine (EPI n = 6) and norepinephrine (NOR, n 
= 6) groups. Hypotensive shock was induced similarly to the previous 
studies with E. coli endotoxin to achieve SAPm < 60mmHg. When 
hypotensive shock was achieved, either an epinephrine or 
norepinephrine infusion was started and adjusted after 4 h, with the 
aim of maintaining SAPm at > 70 mmHg. 
Arterial blood samples were drawn hourly for hemoglobin, arterial 
blood gases, and glucose measurements. Arterial, colonic, mesenteric, 
portal, hepatic, gastric, and mixed venous blood samples were 
collected at baseline and at 0, 2, 3, and 4 h of vasopressor infusion 
(shock 0 h to shock 4 h), and haemoglobin concentration, blood gases 
(model ABL 520; Radiometer, Copenhagen, Denmark), lactate (model 
2300 Stat Plus; Yellow Springs Instruments), and pyruvate (model UV-
706 kit; Sigma, St. Louis, MO) concentrations were analyzed. The 
blood gas analysis of the samples was performed on whole blood 
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immediately after samples were collected into syringes. Dialysate (2 
μl/min) was collected for half an hour before endotoxin infusion, 
before vasopressor infusion, and at the end of the experiment in 30-
min fractions. Microdialysate lactate concentrations were analyzed 
within 15 min (model 2300 Stat Plus; Yellow Springs Instruments, 
Yellow Springs, OH). Microdialysate glycerol concentrations were 
determined (model CMA600; CMA, Stockholm, Sweden) after the 
samples had been stored at -20°C. The flow chart is presented in 
Figure 6. 
 
 
Figure 6. Study flow chart of experiment IV. 
4.4.2 Brain death model 
Following instrumentation, the animals were stabilized for an hour 
and then randomized into one of three groups: dopamine (DOPA, n = 
6), vasopressin (VASO, n = 6) or control (CONTROL, n = 3). The 
baseline hemodynamic parameters, microdialysate, and blood samples 
were collected. A balloon in the epidural catheter was filled in 5-ml 
steps. The further filling of the catheter was discontinued when there 
was no further increase in systemic blood pressure. The anesthesia and 
analgesia were discontinued and not restarted during the experiment. 
Brain death was ensured by monitoring the following clinical signs: 
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dilated pupils with no response to direct light; no cornea reflex; no 
spontaneous breathing; and no response to pain. 
When hypotension was achieved (SAP < 60 mmHg or a 40% drop 
from the baseline) samples were collected at the time point DRUG 0 H. 
The vasoactive drug was started with the aim of increasing the SAPm 
by 15 mmHg, but the maximum infusion rate of vasopressin 
(Pitressin® 20 IU/ml) 0.04 IU/kg/h and dopamine (Dopmin® 40mg/ml) 
20 μg/kg/min was not exceeded. Brain death was induced similarly in 
the CONTROL group, but no vasoactive drug was started when 
hypotension was achieved. The experiment lasted for 5 hours and 
hemodynamic parameters, blood samples, and microdialysate were 
collected hourly. At the end of the experiment, a tissue sample from 
the small gut was collected and preserved in formalin for later 
histological analysis. Arterial and mixed venous blood samples were 
drawn hourly and analyzed for hemoglobin, blood gases, lactate, 
electrolytes, and glucose levels. The study flow chart is presented in 
Figure 7.  
 
 
Figure 7.  Study flow chart of experiment V. 
4.5 MICRODIALYSIS 
The microdialysis capillaries used in experiments I-IV were 
manufactured in our laboratory. The method used has been previously 
validated for intestinal luminal lactate measurement (Tenhunen et al. 
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1999). The capillary membrane of 60 000 Da had a inner diameter of 
the capillary lumen was 200 μm and the length of the semipermeable 
portion was 2.0 cm. The outflow tubing was 100 cm long with an inner 
diameter of 0.134 mm. The in- and outflow tubing were inserted inside 
the tonometer catheter, and the microdialysis catheter was fixed on the 
surface of the tonometer balloon. The microdialysis catheter was 
gently compressed to the gut mucosa by filling the balloon on the 
tonometer. The flow of the microdialysate (Ringer's acetate) was 
adjusted to 2 μl/min, and therefore the delay from the tissue to the 
collecting tubes was 7 min. Tubes were kept on ice during collection. 
Samples were collected in 30-min fractions throughout the experiment 
and microdialysate lactate was analysed within 5 min of fraction 
collection. 
 
4.6  TONOMETRY 
The gastric, jejunal and colonic mucosal partial pressures of carbon 
dioxide were measured with a semiautomatic gas analyser (Tonocap®, 
Datex-Ohmeda, Helsinki, Finland) every 10 min throughout the 
experiment. Tonometric-arterial pCO2 gradients were calculated at 
baseline and hourly thereafter. 
 
4.7  LABORATORY ANALYSES 
After eliminating any air bubbles from syringes, arterial and venous 
haemoglobin and blood gases were analyzed within 5 minutes 
(Hemoxymeter OSM3, Radiometer, Copenhagen, Denmark).  
The enzymatic lactate oxidase method with polarographic 
detection was used for both microdialysate and plasma lactate 
measurements (YSI 2300 Stat Plus, Yellow Springs Instruments Co. 
Inc., Yellow Springs, OH, USA). Whole-blood pyruvate was measured 
enzymatically (Sigmas UV-706 kit, Sigma Diagnostics, St. Louis, MO, 
USA) with spectrophotometric detection (Shimadzu CL-750, Shimadzu 
Corporation, Kyoto, Japan). Pyruvate measurements were performed 
daily.  
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Arterial serum cytokine concentrations (IL-1β and IL-6) were 
determined via porcine immunoassay for IL-1β and IL-6 (Quantikine 
P, R&D Systems Inc., Minneapolis, MN, USA). 
 
4.8  HISTOLOGY 
The samples were analyzed by one person in blinded fashion. The 
specimens were formalin-fixed (pH 7.0), paraffin-embedded (Paramat, 
BDH Laboratory Supplies, Poole, England, melting point 
approximately 58°C), cut into 5-μm sections, and stained with 
haematoxylin and eosin. The focus was on the following histological 
variables: damage to the surface epithelium, inflammation of the 
serosa, and the number of intraepithelial lymphocytes and intramural 
eosinophils. The extent of these variables was graded as 0 = no change, 
1 = mild, 2 = moderate, and 3 = severe changes. 
 
4.9 STATISTICAL ANALYSIS AND CALCULATIONS  
As for to the durations of the endotoxin and vasopressor infusions, the 
study protocols in experiments II-IV were similar. Therefore, the data 
for vasopressin-treated animals have been combined for studies II and 
III, and as have the data for norepinephrine-treated animals for studies 
II and IV. However, the statistical calculations refer to the original 
studies. The data from the studies I and V have been discussed 
separately since the study protocols were different. A convenient 
sampling method was used to determine the number of the animals 
used in each experiment.  
4.9.1 Statistical analysis 
All data are presented as medians with interquartile ranges, except in 
experiment III, for which the data are presented as means with 
standard error. The Mann-Whitney U-test, or a nonparametric test for 
independent samples (Kruskal-Wallis test), was done to evaluate the 
differences between groups at the baseline, before vasopressor 
infusions, and at 4 h when appropriate. Within group analysis was 
done with nonparametric analysis of variance for repeated 
measurements (Friedman test). Wilcoxon’s signed rank test was used 
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for post hoc analysis when a statistical significance was detected by the 
Friedman test. A p-value of < 0.05 was used to indicate statistical 
significance. For the sake of clarity, some of the data has been 
truncated to baseline, hypotensive endotoxin shock before drug 
intervention (Drug/Shock 0 h), and at 4 h from the beginning of the 
drug infusion (Drug/Shock 4 h). 
4.9.2 Oxygen delivery 
Systemic oxygen delivery was calculated as a product of arterial 
oxygen content and cardiac output. For the calculation of mesenteric 
oxygen delivery (DO2mes), the superior mesenteric arterial blood flow 
(Qsma) was used. Total splanchnic blood flow (Qsplalnchnic) was 
calculated as the sum of portal venous and hepatic arterial blood 
flows.  
4.9.3 Carbon dioxide content and content gradients 
Blood carbon dioxide content and regional CO2 content gradients were 
calculated as first devised by Giovannini et al. and applied by Jakob et 
al. (Giovannini et al. 1993, Jakob et al. 1999).  
We calculated the arterial CO2 content (CaCO2) from the bound form 
of carbon dioxide in plasma (CaCO2p) and red blood cells (CaCO2r), 
dissolved carbon dioxide (CaCO2d), and hematocrit (Hct) , and thus, 
 
Ca CO2 = CaCO2p * [1-Hct *(1- CaCO2r/ CaCO2p)] + CaCO2d 
 
We used the Henderson-Hasselbalch equation to determine CaCO2p 
from the partial tension of carbon dioxide in arterial blood (PaCO2) and 
arterial pH (pHa), 
 
CaCO2p = 0.06868 * (PaCO2) * {10[1.04214*(pHa)-6.41036)} 
 
It is known that the ratio (ra) between CaCO2r and CaCO2p is a 
function of plasma pH and oxygen saturation. CaCO2r was then 
determined by using concentration fractions of water in plasma and 
red blood cells of 0.938 and 0.720, respectively:  
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ra = CaCO2r/ CaCO2p = 2.5814 – 0.2640 * (pHa) –  
[0.2203 – 0.0376 * (pHa)] * (1 – SaO2) 
 
 
Finally, CaCO2d was calculated, assuming that the Bunsen 
coefficient for red blood cells is 0.00947 mmHg lower than that of 
plasma: 
 
CaCO2d = PaCO2 * [0.06868 - 0.00947 * (Hct)] 
 
The venous-to-arterial CO2 content gradient was then determined 
from its two components by using the mathematical model described 
by Giovannini et al.: 1) the increase related to the change in partial 
tension of CO2 from arterial to venous blood, and 2) the increase in 
CO2 content related to the change in hemoglobin oxygen saturation 
from arterial to regional venous blood (Haldane effect).  
4.9.4 Haldane effect 
The Haldane effect is a property of hemoglobin whereby 
deoxygenation of the blood increases its ability to carry carbon 
dioxide. Conversely, oxygenated blood has a reduced capacity to carry 
carbon dioxide. In red blood cells, dissolved carbon dioxide is 
converted to carbonic acid, which rapidly dissociates 
into bicarbonate and a free proton: 
 
CO2 + H2O → H2CO3 → H
+
 + HCO3-
 
The enhanced affinity of deoxyhemoglobin for protons enhances 
the synthesis of bicarbonate and increases the capacity of 
deoxygenated blood for carbon dioxide accordingly. The majority of 
carbon dioxide in the blood is in the form of bicarbonate. Only a very 
small amount is actually dissolved as carbon dioxide, and the 
remaining carbon dioxide is bound to hemoglobin. 
In addition to enhancing the removal of carbon dioxide from 
oxygen-consuming tissues, the Haldane effect promotes the dissociation 
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of carbon dioxide from hemoglobin in the presence of oxygen. In the 
oxygen-rich capillaries of the lungs, this property causes the 
displacement of carbon dioxide to plasma as venous blood enters 
the alveolus and is vital for alveolar gas exchange. 
The general equation for the Haldane effect is: 
 
H+ + HbO2 ←→ H
+Hb + O2 
 
The significance of this equation lies in realizing that the 
oxygenation of Hb promotes the dissociation of H+ from Hb, which 
shifts the bicarbonate buffer equilibrium towards CO2 formation, thus 
releasing CO2 from RBCs. 
4.9.5 Respiratory quotient 
During aerobic respiration oxygen is consumed and carbon dioxide is 
evolved. The ratio of the volume of carbon dioxide produced to the 
volume of oxygen consumed in respiration over a period of time is 
called the respiratory quotient (RQ). 
The RQ was calculated as the ratio of regional venous-to-arterial 
CO2 content gradient to regional-to-arteriovenous O2 content gradient. 
The blood O2 content (cO2) was calculated with the standard formula 
of:  
cO2 = [Hb (g/dl) * SaO2 * 1.34 (ml O2/g Hb)] +  
[0.0031 (ml O2 * mmHg-1 * dl-1) * PO2] 
4.9.6 Authors contributions 
The experiments presented here were achieved through collaboration 
between all authors. The research theme and method designing were 
defined by Ruokonen, Tenhunen, Uusaro,  Parviainen, Kurola and 
Martikainen. The laboratory experiments were carried out by 
Martikainen and Tenhunen, with the immeasurable contributions of 
our research nurses. The data was analyzed mainly by Martikainen 
and Tenhunen, with the expertise of Giovannini on the carbon dioxide 
calculations. The interpretation of the results and the writing of the 
manuscripts were accomplished through collaboration between all 
authors. The histological analysis and interpretation were performed 
by Kärjä.   
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5 Results 
 
Dopexamine infusion was started at a dose of 1 μg/kg/min maximal 
infusion rates ranging from 9 to 17 μg kg/min. The median infusion 
rates of vasopressin needed to reverse hypotension were 0.003 (0.002–
0.006) IU/kg/min. The median infusion rates of norepinephrine and 
epinephrine were 0.44 (0.29–0.74) μg/kg/min and 0.60 (0.25-1.60) 
μg/kg/min, respectively.  
 
5.1  SYSTEMIC HEMODYNAMIC CHANGES DURING 
ENDOTOXEMIC SHOCK 
Prolonged endotoxin infusion was caused by a hypotensive shock in 
each animal. Common to all vasoactive drugs studied (except 
dopexamine) was the fact that they effectively reversed the systemic 
hypotension in endotoxin shock (Figure 8). Control animals that 
received endotoxin remained hypotensive or died before the end of 
the experiment. Sham-operated control animals remained stable 
throughout the experiment. 
 
 
Figure 8. Mean systemic arterial blood pressures (SAPm) with interquartile ranges. 
White column = norepinephrine; light gray column = vasopressin; dark gray column = 
epinephrine; striped column = vasopressin + dobutamine. ȘǰȱǛȱȱǙȱȱǀȱŖǯŖśǲȱȱȱȱ
ȱȱȱȱȱȱ¡ȱǰȱȱȱǰȱ¢ǯȱȱ
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Cardiac output (CO) decreased in vasopressin-treated animals. 
After a primary decline in the CO at 30 min caused by a vasopressin 
infusion of 2.3 (1.9 - 3.2) to 1.6 (1.1 - 2.2) l/min p = 0.028, a dobutamine 
infusion reversed the fall of cardiac output within an hour to 2.6 (2.1—
2.7) l/min. Also, epinephrine maintained baseline cardiac output until 
the end of the experiment, and norepinephrine had a strong tendency 
to increase cardiac output (Table 3). Dopexamine reversed the primary 
low cardiac output in the hypodynamic phase caused by endotoxin 
infusion. 
 
Table 3. Cardiac output (ml/min) in the vasopressin, norepinephrine, epinephrine, and 
vasopressin + dobutamine (VasoDobu) groups.  
 
Baseline Shock 0h Shock 4h
Vasopressin 2240(1650-2543) 2345(2260-2628) 1570(1260-2225)  * #
Norepinephrine 2425(2210-2803) 2595(2088-2973) 3920(2738-6215) ¤
Epinephrine 3600(3030-4170) 3640(3225-3770) 3520(3225-4055)
VasoDobu 2400(2130-2460) 2260(1948-3188) 2590(2435-3368)  
*, # and ¤ p < 0.05; p values refer to the results in the original experiments II, III 
and IV, respectively.   
 
5.2 REGIONAL HEMODYNAMIC CHANGES DURING 
ENDOTOXEMIC SHOCK 
In addition to systemic blood flow reduction, vasopressin decreased 
absolute (Qsma) and portal vein (Qporta) blood perfusion, while 
fractional superior mesenteric arterial (Qsma/CO) did not change. 
Simultaneously, the absolute hepatic arterial (Qha), fractional hepatic 
arterial (Qha/CO), and fractional celiac trunk (Qtrunk/CO) blood flows 
increased. Absolute splanchnic (Qsplanchnic) blood perfusion 
decreased, but proportional splanchnic (Qsplanchnic/CO) blood flow 
from the cardiac output did not change in response to the vasopressin 
infusion.  
The    decrease    of    Qsma,  Qporta and   Qsplanchnic   caused by
vasopressin  were   reversed   with  the addition of dobutamine. Qha 
increased, and Qtrunk also had a tendency to increase, even though 
statistical significance was not reached.  
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In response to a norepinephrine infusion, similar adverse 
reductions in regional blood flows were not observed: Qtrunk, Qporta, 
and Qsplanchnic increased, whereas Qsma and Qha were maintained. 
Qtrunk/CO, Qsma/CO, Qporta/CO and Qsplanchnic/CO did not 
change in response to norepinephrine.  
Epinephrine decreased Qporta in five of six animals over the 4-h 
study period, regardless of the direction of change in CO, but 
statistical significance in Qporta within the group did not occur. Both 
Qtrunk and Qtrunk/CO increased in response to epinephrine infusion. 
Qha and Qsplanchnic were maintained.  The regional blood flows are 
presented in Figure 9. 
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Figure 9. Absolute and fractional regional blood flows. White column = 
norepinephrine; light gray column = vasopressin; dark gray column = epinephrine; 
striped column = vasopressin + dobutamine.  
*, # and ¤ p < 0.05; p values refer to the results in the original studies II, III and IV, 
respectively.   
 
In the hypodynamic phase, dopexamine reversed the reduction of 
CO. Dopexamine prevented the reduction in Qsplanchnic, while 
Qsplanchnic/CO decreased. Dopexamine maintained Qtrunk, but 
Qtrunk/CO decreased. Dopexamine reversed the reduction of Qsma 
with a minor reduction in Qsma/CO.  
In the hyperdynamic phase, dopexamine maintained Qsplanchnic 
and Qsplanchnic/CO at baseline levels. Qsma increased with 
increasing proportion of cardiac output. Qtrunk remained constant 
with minor reduction in cardiac output. The regional blood flows 
related to dopexamine-infusion are presented in Table 4.  
 
Table 4. The absolute and proportional regional blood flows in endotoxin shock treated  
with dopexamine.  
 
Baseline Hypodynamic phase Hyperdynamic,hypotensive phase
Qsplanchnic (ml kg–1 min–1) 30 (22–31) 24 (23–28) 35 (34–43)
Qsma (ml kg–1 min–1) 12 (11–13) 15 (12–17) 23 (22–27)*§
Qtrunk (ml kg–1 min–1) 10 (8–12) 10 (9–12) 9 (8–11)
Qsplanchnic/CO (%) 31 (27–31) 19 (17–23)§ 32 (26–34)*
Qsma/CO (%) 12 (12–14) 10 (9–13)§ 20 (17–21)*§
Qtrunk/CO (%) 11 (9–14) 7 (6–8)§ 6 (6–8)*§  
* Friedman’s nonparametric test for repeated measurements (within group analysis); § 
comparison with baseline (Wilcoxon). 
5.3   OXYGEN AND CARBON DIOXIDE METABOLISM IN 
ENDOTOXEMIC SHOCK 
5.3.1 Systemic and regional oxygen delivery and 
consumption 
Systemic oxygen delivery (DO2) and oxygen consumption (VO2) 
decreased and remained low during vasopressin infusion, while 
systemic oxygen extraction increased. Vasopressin also decreased 
mesenteric oxygen delivery (DO2mes) and consumption (VO2mes), and 
increased mesenteric oxygen extraction. Vasopressin did not change 
hepatic oxygen transport. When dobutamine was combined with 
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vasopressin, the adverse effects on systemic and regional oxygen 
delivery, consumption and extraction, were reversed. Norepinephrine 
had no effect on systemic DO2, VO2, or oxygen extraction. 
Norepinephrine did not alter small intestinal or hepatic DO2, VO2, or 
oxygen extraction. Epinephrine had no statistically significant effect on 
systemic or mesenteric DO2, VO2 or oxygen extraction. Epinephrine 
was associated with modestly higher splanchnic oxygen extraction 
than norepinephrine (p = 0.078). The systemic and mesenteric oxygen 
delivery, consumption and extraction are presented in the Table 5.  
 
Table 5. Systemic and mesenteric oxygen delivery, consumption and 
extraction. 
 
Baseline Shock 0h Shock 4h
Systemic oxygen delivery (ml/min)
Vasopressin 284(229-322) 286(254-312) 179(157-207) * #
Norepinephrine 286(255-424) 274(249-322) 365(320-431)
Epinephrine 359(311-429) 362(330-420) 326(274-354)
VasoDobu 307(257-365) 275(206-326) 289(225-306)
Systemic oxygen consumption (ml/min)
Vasopressin 124(109-134) 126(120-150) 116(106-125) *
Norepinephrine 141(128-155) 141(136-155) 165(149-190)
Epinephrine 138(124-165) 161(156-177) 152(149-171)
VasoDobu 122(97-143) 133(132-136) 131(120-139)
Systemic oxygen extraction (%)
Vasopressin 44(40-46) 49(43-53) 63(62-69) * #
Norepinephrine 47(38-53) 52(45-57) 44(41-46)
Epinephrine 44(35-48) 44(39-54) 50(43-58)
VasoDobu 40(33-46) 55(44-59) 51(40-61)
Mesenteric oxygen delivery (ml/min)
Vasopressin 38(31-48) 47(35-54) 19(15-32) * #
Norepinephrine 48(35-58) 40(30-46) 48(36-55)
Epinephrine 56(44-67) 50(38-63) 36(32-57)
VasoDobu 43(40-65) 38(31-41) 28(20-37)
Mesenteric oxygen consumption (ml/min)
Vasopressin 13(11-13) 14(13-18) 11(9-17) *
Norepinephrine 16(15-20) § 21(19-24) 19(17-23)
Epinephrine 17(13-26) 23(18-31) 23(18-29)
VasoDobu 14(12-19) 14(11-16) 14(8-17)
Mesenteric oxygen extraction (%)
Vasopressin 31(28-35) 35(31-48) 55(47-67) *
Norepinephrine 36(29-47) 54(44-61) 43(37-53)
Epinephrine 35(29-42) 38(36-45) 57(47-66)
VasoDobu 29(26-38) 36(26-43) 46(38-48)  
* and #  p < 0.05; p values refer to the results in the original studies II and III, 
respectively.   
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5.3.2 pCO2 and CO2 content gradients  
Arterial pCO2 increased gradually in the norepinephrine group with a 
minor decrease in arterial CO2 content, whereas arterial bicarbonate 
remained stable. The CO2 content gradient remained stable in the 
prehepatic tissues. At the end of the experiment, 23 ± 2% of the CO2 
content gradient over prehepatic tissues could be explained by the 
Haldane effect alone. 
In the epinephrine group, arterial pCO2 increased gradually and 
arterial CO2 content decreased markedly. Concomitantly, arterial 
plasma bicarbonate decreased by 30 ± 3% in the epinephrine group. 
Arterial CO2 content was highly correlated with the bicarbonate 
concentration in the epinephrine group (r2 = 0.94). Epinephrine 
infusion was associated with a more than twofold increase in the 
portal venous-to-arterial pCO2 gradient (from 6.9 ± 0.7 at baseline to 
15.6 ± 2.5 mmHg at the end of the experiment, p < 0.05), but only a 
minor (25%) increase in the portal venous-to-arterial CO2 content 
gradient, from 3.9 ± 0.3 to 4.9 ± 0.7 ml/dl. At the end of the experiment, 
20 ± 1% of the CO2 content gradient over prehepatic tissues could be 
explained by the Haldane effect only. Epinephrine induced a marked 
increase in the venous-to-arterial pCO2 gradient in the stomach and a 
true increase in the CO2 content gradient with only 16 ± 3% accounted 
for by the Haldane effect compared with norepinephrine-treated 
animals in which both the pCO2 and CO2 content gradients remained 
low with 25 ± 1% accounted for by the Haldane effect. 
The mesenteric venous-to-arterial pCO2 gradient had a tendency to 
increase (p = 0.075) twofold after 4 h of epinephrine, whereas 
norepinephrine was associated with a low mesenteric pCO2 gradient. 
The mesenteric CO2 content gradient was constant in both the 
epinephrine and norepinephrine groups. The Haldane effect explained 
19 ± 1 and 25 ± 1% of the CO2 content gradient at the end of the 
experiment in the epinephrine and norepinephrine groups, 
respectively. We detected a 75 ± 19% increase in the colonic venous-to-
arterial pCO2 gradient in the colon after 4 h of epinephrine infusion, 
while, the venous-to-arterial CO2 content gradient remained constant. 
The regional pCO2 gradients, content gradient and the influence of the 
Haldane effect are presented in Figure 10.  
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Figure 10. Regional gastric (top row), jejunal (middle row), and colonic (bottom row) 
venoarterial (v-a) CO2 partial tension gradients (left panels), venoarterial CO2 content 
gradients (middle panels), and proportional magnitude of the Haldane effect (right 
panels) in epinephrine (white) and norepinephrine (gray) -treated animals at the 
baseline, after hypotensive endotoxin shock was established (0 h) and after 4 h of 
vasopressor infusion (4 h). * P < 0.05, within the group (shock 0 h–4 h, Friedman test). 
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5.3.3 Tonometry 
Vasopressin infusion was associated with increasing mucosal-arterial 
pCO2 gradients in the stomach, colon, and jejunum, whereas the four-
hour norepinephrine treatment had no effect on mucosal-arterial pCO2 
gradients. Dopexamine reversed the colonic mucosal to arterial pCO2 
gradient while it increased the pCO2 gradient in stomach.    
 
5.4 LACTATE AND PYRUVATE 
5.4.1 Systemic lactate 
During the 4-h period of vasopressin infusion, arterial lactate 
increased from 2.0 mmol/l (1.8 –2.2 mmol/l) to 4.7 mmol (2.8 – 5.6 
mmol/l) (p < 0.001). Dobutamine reversed the systemic 
hyperlactatemia caused by vasopressin. Norepinephrine did not 
change the arterial lactate concentration. Arterial lactate increased 
fivefold (p < 0.001) in animals treated with epinephrine. Dopexamine 
infusion was associated with marked arterial hyperlactataemia with an 
increasing systemic lactate to pyruvate (L/P) ratio. Arterial lactate 
concentrations are presented in Figure 11. 
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Figure 11. Arterial lactate concentrations (mmol/L). White column = norepinephrine; 
light gray column = vasopressin; dark gray column = epinephrine; striped column = 
vasopressin + dobutamine and. 
 *, # and ¤ p < 0.05; p values refer to the results in the original studies II, III and IV, 
respectively.   
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5.4.2 Regional lactate and pyruvate 
Mesenteric, gastric, colonic, and hepatic venous-arterial lactate 
gradients increased in animals treated with vasopressin. Venous-
arterial lactate gradients did not increase in any region in the DOBU 
group in contrast with sole vasopressin infusion. Neither were there 
changes in regional lactate gradients in the norepinephrine group. The 
gastric venous-to-arterial lactate gradient had a tendency to increase in 
animals treated with epinephrine.  
Regional arterial and venous lactate-pyruvate (L/P) ratios increased 
in all areas in the VASO group. Dobutamine prevented increases in 
regional L/P ratios. The arterial lactate-to-pyruvate ratio and the 
regional venous lactate-to-pyruvate ratios increased in all monitored 
areas in the epinephrine group.  
In the hypodynamic phase, dopexamine was associated with 
negative veno-arterial lactate gradients over the stomach, jejunum and 
colon with increased L/P ratios in the stomach and jejunum. There 
were no changes in hepatic lactate turnover. In the hyperdynamic 
phase, dopexamine increased the gastric veno-arterial lactate gradient 
and the L/P ratio exceeded the baseline, while the veno-arterial lactate 
gradients in the jejunum and colon remained at baseline. The regional 
lactate gradients are presented in Table 6.  
 
Table 6. Regional lactate gradients.  
Baseline Shock 0h Shock 4h
Mesenteric lactate gradient (mmol/L)
Vasopressin 0.1(0.1-0.2) 0.2(0.0-0.3) 1.2(0.4-1.5) #
Norepinephrine 0.1(0.1-0.3) 0.1(0.0-0.2) 0.1(0.0-0.1)
Epinephrine 0.2(0.1-0.4) 0.4(0.3-0.6) 0.0(-0.2-0.1)
VasoDobu 0.1(0.0-0.2) -0.1(-0.2-0.1) 0.1(0.1-0.2)
Colonic lactate gradient (mmol/L)
Vasopressin 0.3(0.3-0.4) 0.3(0.2-0.5) 1.4(0.9-2.1) *, #
Norepinephrine 0.5(0.4-0.6) 0.3(0.2-0.5) 0.2(0.1-0.4)
Epinephrine 0.4(0.3-0.5) 0.3(0.3-0.4) 0.3(-0.2-0.5)
VasoDobu 0.3(0.3-0.5) 0.3(0.2-0.5) 0.3(0.2-0.4)
Gastric lactate gradient (mmol/L)
Vasopressin -0.1(-0.2-0.0) 0.0(-0.1-0.8) 1.2(0.0-3.8) *
Norepinephrine 0.0(-0.1-0.1) 0.1(-0.1-0.4) 0.6(-0.2-1.8)
Epinephrine 0.1(0.0-0.1) 0.6(0.1-1.1) 1.3(1.2-1.8)
VasoDobu -0.1(-0.1-0.0) 0.2(-0.1-0.6) 0.4(0.0-0.8)  
* and # p < 0.05; p values refer to the results in the original studies II and III, 
respectively.   
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5.4.3 Luminal and intraperitoneal lactate and pyruvate 
Vasopressin infusion was associated with luminal lactate release in the 
jejunum. Lactate could not be detected at the baseline, whereas at 4 h, 
the median luminal lactate concentration in the jejunum was 3.0 
mmol/l (1.6 – 4.4 mmol/l; P = 0.001). There was no luminal lactate 
release in the stomach or colon in the VASO group. Intraperitoneal 
lactate concentration increased on the surface of the colon and jejunum 
in the VASO group from 1.3 (1.1 to 1.8) to 1.6 (1.1 to 3.6) mmol/l (p = 
0.028) and from 1.6 (1.5 - 2.5) to 2.3 (1.7 - 4.1) mmol/l (P = 0.046), 
respectively. Intraperitoneal lactate release occurred on the surface of 
the jejunum in the epinephrine group as well. Furthermore, 
epinephrine increased the intraperitoneal glycerol concentration. 
There was no increase in the intraperitoneal lactate concentration in 
the DOBU group. Luminal lactate release did not occur in the 
norepinephrine group.  
 
5.5 INTERLEUKINS 
The animals receiving endotoxin had normal IL-1 and IL-6 
concentrations at the baseline and increased substantially in response 
to endotoxin, whereas there was no change in the controls. 
Dopexamine did not modify this cytokine response. Serun interleukin 
concentrations are presented in Figure 12. 
 
Figure 12. Serum interleukine (IL)-1ß and IL-6 concentrations at baseline and at the 
end of the experiment. Statistical analysis was done with the Friedman test from 
baseline to drug 4 h. Grey column; ETX (n=6), white column; VASO (n=6), black 
column; NE (n=6), diagonal column; CONTROL (n=3). Statistical significances are 
marked with *.  
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5.6  HEMODYNAMIC CHANGES IN BRAIN DEATH MODEL 
Brain death caused hypotension in each animal. One animal in the 
dopamine group and one animal in the control had a cardiac arrest 
before the end of the experiment. The median infusion rates during the 
experiment were 10.8 (10.5-11.0) μg/kg/min for dopamine and 0.02 
(0.01-0.03) IU/kg/h for vasopressin.  
There were no differences in SAPm at DRUG 0 h. Vasopressin 
reversed the hypotension induced by brain death, but in the dopamine 
group, the target SAPm was not achieved despite the predermintaed 
maximun infusion rate. The control group remained hypotensive 
through the end of the experiment.  
CO was comparable between groups at DRUG 0 h. CO had a 
tendency to increase after the initiation of dopamine infusion, but 
remained at approximately the same level at the end of the 
experiment. CO decreased during vasopressin infusion, while the 
heart rate did not significantly change. Dopamine was associated with 
increasing heart rate, from 176 (157-205) 1/min to 222 (187 - 230) 1/min 
(Figure 13).  
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Figure 13. A) Cardiac output (L/min), B) heart rate (beats/min). Black line = 
dopamine; gray line = vasopressin. * p < 0.05 Friedman test, drug 0 h – 5 h.  
 
The Qsma increased and remained elevated in the dopamine 
group, while the Qsma/CO remained unchanged. Dopamine was 
associated with a minor decrease in the Qtrunk/CO.  Vasopressin 
decreased the Qsma, and the Qsma/CO also had a tendency to 
decrease (p = 0.078). Vasopressin showed no significant change in 
celiac trunk blood flow. The regional blood flows are presented in 
Table 7.  
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Table 7. The absolute and regional blood flows. Friedman test drug 0 h – 5 h. § = 
Kruskal-Wallis test at baseline, p = 0.024. 
 
 
 
 
5.7   METABOLIC AND OXYGEN TRANSPORT CHANGES IN 
BRAIN DEATH MODEL 
Systemic oxygen delivery, consumption and extraction remained 
stable in the DOPA group, while systemic oxygen delivery and 
consumption decreased in the VASO group, and oxygen extraction 
increased.  
Initially, dopamine seemed to increase mesenteric oxygen delivery, 
eventually regaining its original level. Vasopressin decreased SMA 
oxygen delivery, but celiac trunk oxygen delivery did not change. 
Systemic and regional oxygen data are presented in Table 8.  
 
 
 
 
 
BL DRUG 0H DRUG 5H Friedman Drug 0h - 5h 
Qtrunk (ml min -1 ) 
DOPA 389(357-727) 318(222-488) 404(257-462) 0.621 
VASO 294(231-309) 250(232-325) 267(244-493) 0.522 
Qsma (ml min -1 ) 
DOPA 680(645-699) § 729(581-897) 954(945-1163) 
VASO 534(487-593) 495(446-543) 295(252-357) 0.016 
Qtrunk/CO (%) 
DOPA 7(6-8) 7(5-11) 6(5-8) 0.046 
VASO 6(5-7) 6(5-8) 9(8-10) 0.210 
Qsma/CO (%) 
DOPA 10(9-13) 14(13-15) 16(16-17) 0.402 
VASO 12(11-12) 14(10-14) 8(7-10) 0.078 
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Table  8. Oxygen delivery, consumption and extraction. . Friedman test Drug 0h – 5h. 
§ = Kruskal-Wallis test at baseline, p < 0.05.  
 
BL DRUG 0H DRUG 5H Friedman 
Systemic oxygen delivery (ml min-1) Drug 0h - 5h
DOPA 619(570-679) 533(508-716) 511(495-512) 0.430
VASO 434(413-529) § 458(346-535) 354(272-470) 0.002
Systemic oxygen consumption (ml min-1)
DOPA 157(151-176) 220(161-239) 170(170-174) 0.146
VASO 127(121-136) § 174(136-186) 142(116-166) 0.009
Oxygen extraction (%)
DOPA 24(22-28) 36(31-43) 33(33-33) 0.905
VASO 28(24-33) 36(31-38) 40(33-44) 0.024
SMA oxygen delivery (ml min-1)
DOPA 72(69-77) 82(72-108) 84(83-102) 0.100
VASO 54(49-63) § 51(44-60) 39(24-40) 0.019
Trunk oxygen delivery (ml min-1)
DOPA 43(36-70) 37(25-55) 29(27-43) 0.262
VASO 30(23-32) 30(28-33) 25(24-58) 0.446
 
There was an initial arterial hyperlactatemia, which decreased to a 
normal level by the end of the experiment in all groups. There was no 
significant lactate release or changes in the lactate/pyruvate ratios in 
any group. Despite the initial hyperlactatemia, there were no 
significant systemic or regional changes in lactate or pyruvate 
concentrations.  
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6 Discussion 
6.1 MAIN FINDINGS 
The main findings of this series of experiments are as follows: 1) 
Dopexamine decreased the proportional splanchnic blood perfusion 
despite the increasing cardiac output in hypodynamic shock. During 
hyperdynamic shock, dopexamine decreased the proportional celiac 
trunk blood flow, which was associated with increasing gastric 
mucosal to arterial pCO2 gradients and gastric luminal lactate release. 
These findings together suggest that dopexamine caused selective 
gastric mucosal hypoperfusion in the prolonged endotoxin shock. 2) 
Vasopressin caused systemic, but more interestingly, selective 
mesenteric hypoperfusion, regardless of the given dosage. In addition 
to decreased cardiac output and superior mesenteric arterial blood 
flow, vasopressin caused systemic hyperlactatemia, an increase in the 
mucosal to arterial pCO2 gradient, decreases in systemic and 
mesenteric oxygen delivery, and remarkable lactate release in the 
small gut. 3) When vasopressin was combined with dobutamine, none 
of the previously stated adverse effects occurred. 4) Epinephrine 
caused severe systemic lactatemia, but the majority of the lactate was 
possibly released from tissues other than viscera; thus, systemic lactate 
measurement is not reliable for assessing the splanchnic perfusion. 
Epinephrine decreased arterial CO2 content and plasma bicarbonate 
concentration. The portal venous-to-arterial pCO2 gradient increased 
with an only minor increase in the CO2 content gradient. Interestingly, 
both the pCO2 gradient and the true CO2 content gradient increased in 
the stomach, as did the gastric venous-to-arterial lactate gradient. 
These results indicated that epinephrine maintains overall splanchnic 
perfusion, but causes regional adverse effects on gastric perfusion and 
metabolism. 5) Norepinephrine preserved systemic and splanchnic 
perfusion, and no adverse metabolic changes were noticed, even 
though occasional high infusion rates were used. 6) After experimental 
brain death, low-dose vasopressin was effective in the treatment of the 
subsequent systemic hypotension, but compromised both systemic 
and especially small bowel blood flow and oxygen delivery. 
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Oppositely, the systemic hypotension was not effectively treated with 
dopamine, but systemic and small bowel blood perfusions were 
maintained.  
 
6.2   COMPARISON OF VASOACTIVE DRUGS ON 
SPLANCHNIC PERFUSION AND METABOLISM 
6.2.1 Norepinephrine 
Our studies are in consensus with several others, suggesting that 
norepinephrine is a potent and safe vasopressor, and increasing the 
dosage increased splanchnic blood flow rather than decrease it. 
Neither did we notice any disadvantages of the systemic or regional 
oxygen transport related to norepinephrine, unlike vasopressin and 
epinephrine. Also, systemic and regional lactate levels remained low 
on norepinephrine-treated animals, and there were no significant 
lactate releases from the mucosa of the gut as estimated using 
microdialysis.   
Probably the most traditional and commonly used, and 
recommended by the Surviving Sepsis Campaign (Dellinger et al. 
2008), first line vasoactive agent in the treatment of hypotension and 
hypoperfusion is norepinephrine. It is known to be a potent 
vasoconstrictor in hypotensive septic shock, and it seems to be 
relatively safe concerning splanchnic circulation (Levy et al. 1997, 
Zhou et al. 2002). There is evidence that when combined with 
adequate volume resuscitation, norepinephrine increases mesenteric 
blood flow and decreases lactate levels in experimental septic shock 
(Sennoun et al. 2007). According to Treggiari et al., there is no further 
advantage for splanchnic blood flow when a norepinephrine infusion 
is increased to increase SAPm by 20mmHg above the shock level. On 
the other hand, increasing the norepinephrine infusion rate seems not 
to have deleterious effects on splanchnic perfusion (Treggiari et al. 
2002). Also, controversial studies exist on the safety and beneficial 
effects on splanchnic circulation: according to the study of Krejci et al., 
norepinephrine may compromise the jejunal microcirculation (Krejci et 
al. 2006). This study, however, had limitations on the study setting: the 
experiment was performed with a crossover design in which different 
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vasoactive drugs were infused one after another. However, in 
catecholamine-resistant septic shock, dosages may rise extremely high, 
and the effects on splanchnic circulation remain unclear.  
6.2.2 Epinephrine 
Epinephrine seemed to preserve splanchnic blood according to regional  
blood flows. However, both gastric venous  to  arterial  pCO2 and CO2
content gradients increased. Also,   systemic,  and   especially   regional,
L/P ratios   increased   during    the   epinephrine   infusion,   suggesting 
that   epinephrine   may  have  undesirable   effects  on  tissue perfusion.
Pyruvate, an end product of aerobic glycolysis,  is reduced  to lactate in 
anaerobic conditions. Therefore, an  increased lactate  to  pyruvate ratio 
(L/P) is one marker of anaerobic metabolism. In addition, we detected a 
high  systemic  lactate,  which  was  apparently  mostly  released   from 
tissues   other  than  viscera.   Therefore  the  evaluation  of   splanchnic 
perfusion  according  to  lactate  exchange  is limited.  Our experiments 
suggest that epinephrine indeed has detrimental effects on  splanchnic   
circulation, and especially on gastric microcirculation  and metabolism. 
 
   
        We  did   not   measure  the direct  changes in  microcirculation; the 
assessment of splanchnic circulation was made according to the blood 
flow of the major vessels in the splanchnic area. As stated before, the 
assessment  of  splanchnic  circulation is  very challenging. This may 
be one reason, why the outcomes of the different studies according to 
the effects of epinephrine on the splanchnic circulation are so 
conflicting (De Backer et al. 2003, Seguin et al. 2002, Duranteau  et al. 
1999).   
    . When  the  other  catecholamines  fail to reverse hypotension in septic  
shock, epinephrine is effective in restoring  the global hemodynamics, 
primarily by increasing systemic vascular resistance and heart rate 
(Wilson et al. 1992). However, systemic hyperlactatemia is regularly 
associated with the use of epinephrine. It is still a matter of debate 
whether hyperlactatemia is a sign of impaired splanchnic perfusion 
(Meier-Hellmann et al. 1997) or if it contributes to defective oxidative 
metabolism (Levy et al. 2005).  
It  is  practically  impossible  to  distinguish  the origination of  lactate
 only by  evaluating  arterial lactate. Thus,  lactatemia  is  not inevitably
 a  sign  of  splanchnic  hypoperfusion.   Because  of  the    distinctive
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properties of the splanchnic organ anatomy and vasculature, 
macrocirculation does not necessarily correlate to cell oxygen 
metabolism. Therefore, we wanted to assess the regional splanchnic 
perfusion and metabolism not only by measuring regional blood 
flows, but also by calculating regional venous-to-arterial pCO2 
gradients, CO2 content gradients and the magnitude of the Haldane 
effect on venous-to-arterial CO2 gradients. Tonometry has been used to 
assess gastric perfusion by measuring the partial tension of CO2 (Joly 
et al. 1999, Creteur et al. 1999). However, pCO2 does not necessarily 
mirror the actual carbon dioxide content in the tissue and organ 
perfusion due to its rather complicated behaviour around different 
surrounding factors, such as alternating pH, bicarbonate and 
haemoglobin saturation.  
6.2.3 Dopexamine 
Dopexamine decreased the proportional splanchnic blood flow, while 
cardiac output increased during the hypodynamic phase of the shock. 
Also celiac trunk flow decreased, and the gastric mucosal to arterial 
pCO2 gradient and luminal lactate increased, indicating probable 
mucosal dysoxia. These findings were reversed in the colon. With a 
prolonged shock phase, total splanchnic perfusion was restored, but 
redistribution of blood flow was noted by decreased celiac trunk flow 
in the direction of increased superior mesenteric artery perfusion. 
Since the blood flow to the stomach is mainly supplied from the 
branch of the celiac trunk, it is possible that the blood flow was not 
sufficient to match the increased metabolic rate of the gastric mucosa.   
Because of both its vasodilative and inotropic effects, dopexamine 
is an attractive choice in attempting to preserve the splanchnic 
circulation in cases of septic shock. In combination with 
norepinephrine, it has been shown to enhance gastric mucosal blood 
perfusion (Seguin et al. 2006). However, in another study, dopexamine 
decreased gastric pHi, suggesting a harmful effect on gastric mucosal 
perfusion even though splanchnic perfusion was increased in same 
proportion as cardiac output (Meier-Hellmann et al. 1999).  
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6.2.4 Vasopressin 
Common to all infusion rates used (from low 0.02 IU/kg/h to high 0.42 
IU/kg/h) was the amount needed to achieve the goal of systemic mean 
arterial pressure; both cardiac output and superior mesenteric artery 
blood flow was decreased, whereas Qha and Qha/CO increased. Also, 
systemic and mesenteric oxygen delivery decreased with increased 
oxygen extraction. With the higher infusion rates, systemic and 
regional lactate release also occurred, indicating not only systemic, but 
also inadequate regional perfusion.  In our experiment III, the 
deleterious effects of vasopressin on systemic and regional 
hemodynamics and metabolism were compensated when combined 
with dobutamine, apparently securing the tissue perfusion.  
Most of our results are equivalent those of others (Hiltebrand et al. 
2007). However, with low-dose vasopressin, superior mesenteric 
arterial blood flow may not be compromised (Sun et al. 2003), and 
there are references that the adverse effects of vasopressin on 
splanchnic circulation may indeed be dose-related (Asfar et al. 2005, 
Kopel et al 2008). The decrease of systemic blood flow and oxygen 
delivery associated with vasopressin has been also noted by others 
(Albanése et al. 2005). As a result, interest in combining vasopressin 
with an inotrope, such as dobutamine, has emerged. Dobutamine has 
been shown to improve mesenteric blood flow and gastric 
intramucosal pH in an experimental shock model (De Backer et al. 
1996). Our data from vasopressin combined with dobutamine is 
supported by Morelli et al., where a single dose of terlipressin 
combined with dobutamine increased SAPm, markedly decreasing the 
need for norepinephrine and increased the SvO2 (Morelli et al. 2008). 
According to another study, a continuous infusion of low-dose 
terlipressin did not have deleterious effects on systemic or splanchnic 
area circulation, and it was considered as safe as a first-line 
vasopressor in septic shock (Morelli et al. 2009).  
In the brain death model, despite the low dosage of vasopressin, 
similar hemodynamic changes were noted as with higher dosages in 
endotoxemic shock models: SAPm was achieved; cardiac output 
decreased; absolute and fractional SMA blood flow decreased; and 
systemic and SMA oxygen delivery decreased.  However, systemic 
arterial lactate release occurred only at the beginning of the 
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experiment, apparently related to the catecholamine storm induced by 
brain death.  
Even though vasopressin compromised systemic and mesenteric 
blood flow and oxygen delivery, we did not register lactate release 
from the jejunum, nor were there significant changes in the histology 
of the jejunal wall. It is possible that if hypoperfusion had lasted 
longer vasopressin would have compromised the vitality of the small 
gut. In the management of organ donor hemodynamics, vasopressin is 
a tempting agent for two reasons: first, it is known to be a potent 
vasopressor and reduces the need of catecholamines, and second, the 
damage of the posterior pituitary causes the ceasation of vasopressin 
storage after brain death (Gramm et al. 1992). Therefore, it would be 
reasonable to assume that the administration of exogenous vasopessin 
would be beneficial. Indeed, among other supportive therapies such as 
volume resuscitation, hormonal treatment and aggressive respiratory 
therapy, vasopressin has been recommended as the initial therapy for 
hemodynamic support by the American College of Cardiology (Hunt 
et al. 1996).  
Since higher vasopressin dosages (>0.04 IU/min) are related to 
potentially deleterious vasoconstriction of renal, mesenteric, 
pulmonary, and coronary vasculature (Holmes et al. 2001), we did not 
exceed that dosage. The infusion rate of 0.04 IU/min was not exceeded 
at any point, and the median infusion rate was 0.01 (0.005 - 0.015) 
IU/min.  
Vasopressin, or its analogues, has been successfully used in the 
hemodynamic management of pancreatic (Decraemer et al. 2004), 
kidney (Guesde et al. 1998) and heart donors (Venkateswaran et al. 
2009). However, since vasopressin seems to deteriorate mesenteric 
perfusion, it should not be used as a sole vasopressor in small intestine 
donor treatment. The effects of vasopressin combined with some 
inotropic agent on mesenteric blood flow would be of interest for 
further research.  
6.2.5 Dopamine 
In our experiment V, target SAPm (>75 mmHg) was not achieved, 
even at the maximum dosage. However, cardiac output and especially 
mesenteric perfusion was increased, and no harmful systemic or 
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regional metabolic effects were observed. It is probable that the 
achieved SAPm (70 mmHg) is sufficient to maintain splanchnic 
perfusion. According to De Backer et al., dopamine may maintain 
splanchnic perfusion in septic shock, as does norepinephrine (De 
Backer et al. 2003). 
Dopamine has been a traditional inotrope in the treatment of organ 
donors. However, it has been reported to suppress the function of 
pituitary hormones, and its beneficial effect on renal and 
hepatosplanchnic circulation has been questioned (Debaveye and van 
den Berghe 2004). However, in a recent, relatively large study by 
Schnuelle et al., low-dose dopamine (4 μg/kg/min) reduced the need 
for dialysis after kidney transplantation (Schnuelle et al. 2009). Further 
on, since dopamine may cause unfavorable cardiac events in the 
treatment of organ donors, a new approach with a non-hemodynamic 
derivative of dopamine has been shown to protect allografts from the 
deleterious events of cold ischemia (Lösel et al. 2010).   
Several reviews have evaluated which vasopressor would be “the 
drug of choice” in the treatment of septic shock, but a clear benefit 
remains elusive. There is some evidence that vasopressin could reduce 
mortality in certain patient groups (Russell et al. 2008), but more 
research is needed. Because of the dynamic nature of septic shock and 
the great diversity of patients, co-morbidies, etc., it is reasonable to 
assume that one vasoactive drug cannot suit all. In contrast, clinicians 
should carefully evaluate the possible risks and benefits within every 
patient, and possibly combine two or maybe even three vasoactives to 
maximize the benefits of different agents.    
 
6.3    METHODOLOGICAL CONSIDERATIONS 
Several different septic shock models have been used in experimental 
studies, but currently, the two main strategies are: 1) the release of 
feces into the peritoneal cavity, or 2) injecting bacteria or its 
components, such as endotoxin, into the blood stream (Rittirsch et al. 
2006). Both methods have certain advantages and disadvantages. We 
used the latter for its repetitiveness and for its similarities with human 
sepsis. Endotoxin infusion causes systemic inflammation that mimics 
many of the initial clinical features of sepsis, including increasing 
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proinflammatory cytokines such as TNF-α and IL-1 (without 
bacteremia) (Remick et al. 2000), even though the increase is more 
intense than in human sepsis (Doi et al. 2009). The similarities between 
humans and pigs, especially concerning cardiovascular and 
gastrointestinal anatomy, and physiology make pigs appropriate for 
experimental models (Fink and Heard 1990). With smaller animals, 
such as rodents, there are several disadvantages concerning the septic 
shock model: it is difficult to measure systemic (CO, PAOP, 
pulmonary pressure, etc.) and regional blood perfusion; the blood 
samples that can be drawn are limited since the total amount of blood 
is small; and several hours of controlled ventilation is virtually 
impossible, just to name few.   
We used a prolonged sepsis model, i.e., 10-18 hours of endotoxin 
infusion, to achieve hypotensive, hyperdynamic (low systemic 
vascular resistance) hemodynamic state, similar to that seen in patients 
with septic shock. We also had full-scale hemodynamic monitoring 
and performed rigorous blood gas analysis throughout the 
experiment, including stabilization time, in order to maintain optimal 
fluid and respiration balance.  
For our brain death model, we used a stepwise filled balloon in the 
epidural space to increase intracranial pressure for causing brain 
death. A similar method has been used and validated by others (Chen 
et al. 1996, Bittner et al. 1995). We noticed a typical Cushing reflex in 
each animal (tachycardia, extreme hypertension), which led to 
hypotension. We did not use an EEG or other device to ensure the 
diminishing of brain activity since we had no such device validated for 
animals. Instead, we used typical methods to evaluate clinical brain 
death: no spontaneous breathing, dilated pupils with no reflex to 
straight light, and no reaction to pain stimuli. Also, anesthesia was 
discontinued after hypotension was achieved and was not started 
again during the experiment. The sedative effects of propofol and 
fentanyl were reliably diminished during the study protocol (5 hours); 
the elimination half-life of propofol being around 30 – 60 minutes; 
medetomidine 1-2 hours; ketamine 80 minutes; and midazolam 30 
minutes.   
It may seem irrelevant to compare two seemingly different models 
of endotoxemic shock and brain death. Our main interest in the whole 
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series of studies was the effects of the vasoactive agents on systemic, 
and especially on splanchnic circulation and metabolism. Since both of 
these disorders regularly require vasoactive medications to support 
tissue perfusion, we thought it would be reasonable and comparable 
to discuss these together. Obviously, the mechanisms behind these 
perfusion deficits are different, but there is at least one other common 
mediator: according to several studies, vasopressin depletion occurs 
both in septic shock (Sharshar et al. 2002) and soon after brain death 
(Gramm et al. 203). The use of vasopressin is increasing in 
(catecholamine-resistant) septic shock, and it is also recommended in 
the management of hemodynamics on brain death organ donors if 
catecholamines fail to secure systemic perfusion. We were aware, 
according to the literature and to our previous studies, that this may 
compromise mesenteric circulation. Therefore, we limited the 
vasopressin infusion rate to below 0.04 IU/min in the brain death 
model, which has been considered safe. In our endotoxin shock model, 
vasopressin infusion rates climbed above these recommendations 
since achieving a pre-determinated mean systemic arterial pressure 
was the only target for regulating infusion rates. However, there have 
been controversial results concerning low-dose vasopressin and 
mesenteric blood perfusion (Asfar et al. 2005, Westphal and Traber 
2005). 
 
6.4  LIMITATIONS 
There are obvious limitations to our studies. Experimental results 
should never be extrapolated straight to clinical work because of the 
possible species differences, even though pigs resemble humans both 
physiologically and anatomically. As long as there are no clinically 
relevant, easy to use, continuous and merely non-invasive methods for 
evaluate splanchnic blood flow, we have to base our decisions, at least 
in part, on the experimental models. The number of the animals 
needed in each experiment was determined by convenient sampling 
method. Therefore, it is possible that some results lacking statistical 
significance would have turned out significant if a larger sample size 
had been chosen. It is also possible that because of the limited sample 
size there was occasional diversity between different hemodynamic or 
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metabolic parameters between groups at baseline. However, for most 
of the results, the trends of the parameters were consistent, and the 
main findings between different series were coherent. For example, in 
experiment IV, the hemodynamic parameters that differed at baseline 
favored the epinephrine-group over the norepinephrine-group, yet 
epinephrine induced more severe metabolic changes at the end of the 
experiment. The sepsis model we used, endotoxin infusion, may not 
resemble human septic shock in the best possible way. However, the 
“ideal” sepsis mode has yet to be discovered; all current models have 
some dissimilarities to human septic shock. We focused our vasoactive 
treatment solely on one parameter; mean arterial pressure, 
disregarding other vital signs. To our understanding, this was the only 
reasonable way to assess the efficiency and differences of 
vasopressors. We used PAOP at 5-7 mmHg for the estimation of 
normovolemia, but it is possible that some animals were hypovolemic. 
However, if SAPm was below 50 mmHg, fluid resuscitation of 
Ringer’s acetate or colloid of 100-200 ml was given, aiming for a PAOP 
of 8-9 mmHg. In some cases, fluid resuscitation was not possible 
because of high pulmonary arterial pressure or a CVP over 16 mmHg. 
There may be several explanations why normoventilation was not 
achieved with all animals: possible lung injury caused by endotoxin, 
atelectasis, pulmonary edema, or pleural fluid. It has been reported 
that an acute increase in arterial pCO2 may alter systemic and 
splanchnic blood flow (Losser et al. 2010). Therefore, we cannot rule 
out the possible hemodynamic effects of hypoventilation in our 
experiments, even though there were no statistical differences between 
groups concerning arterial pCO2 concentrations. Vasopressor infusion 
rates were high, but that was unavoidable because the only target was 
achieving the pre-determinated SAPm. For example, in experiment II 
and IV the vasopressin infusion rates were much higher than 
recommended, but norepinephrine infusions were also high without 
exhibiting deleterious effects. It could have been reasonable to use 
terlipressin, the synthetic anaogue of vasopressin, because of its longer 
elimination half-life and greater affinity to V1 receptors. Vasopressin 
was chosen merely because of its better availability at the time of the 
first experiment, and it did not seem reasonable to chance it during the 
series of experiments. What we did chance was the anesthetics for the 
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sedation and induction, and for the last experiment we used propofol 
for the maintenance of the anesthesia instead of thiopentone. The 
reasons for the changes were that we wanted to find the best 
combination of sedation anesthetics to secure spontaneous breathing, 
stable hemodynamics and minimize saliva production before the 
airway was secured. It is reasonable to assume that changing the 
medications for the sedation or anesthesia did not cause significant 
bias in the hemodynamic or metabolic parameters for three reasons: 1) 
the relatively short elimination half-life of the anesthetics used for 
sedation; 2) the long duration of the experiment; and 3) the similar 
hemodynamic effects of propofol and sodium thiopentone. In the last 
experiment, no significant cell damage was noted even though 
reduced mesenteric perfusion occurred in the vasopessin group. It is 
possible that small gut hypoperfusion was not long or severe enough 
to cause histological changes, and it is possible that cell ischemia or 
negrosis could have occured if the hypoerpfusion had lasted longer. 
Regardless of the reason, it is obvious that perfusion to the organs 
being transplanted, in this case the small gut, should be optimized in 
order to secure successful transplantation.     
  
6.5 CLINICAL IMPLICATIONS 
Because of the complicated etiology of sepsis, including the complex 
nature of pro- and anti-inflammatory cascades, it is rational to argue 
that the treatment should be versatile. In other words, early diagnosis, 
early volume resuscitation and antibiotic therapy, source control and 
vasoactive therapy are still the cornerstones in the treatment of sepsis. 
According to our studies, only norepinephrine seemed to reverse the 
tissue perfusion deficit without causing adverse effects on splanchnic 
perfusion. Regardless of the promising nature of dopexamine, it did 
not selectively improve splanchnic circulation. Furthermore, 
particularly adverse metabolic effects on the gastric area were 
concerning. Epinephrine also caused systemic hyperlactatemia, which 
is commonly seen clinically, and according to our experiment, is not 
safe as a first-line vasopressor because of its possible negative effects 
on splanchnic and, especially, gastric perfusion. It is frustratingly 
common that patients with severe septic shock develop a state of 
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shock that is resistant to catecholamines. In such cases, additional 
vasoactives, other than catecholamines, are needed. Vasopressin alone 
reversed the systemic hypotension, but had detrimental effects, 
especially on mesenteric blood flow. However, it seemed to be a good 
alternative when combined with dobutamine. In addition to the 
endotoxin shock model, vasopressin also showed detrimental effects 
on mesenteric blood perfusion in the brain death model, whereas 
dopamine secured the splanchnic blood flow.  Perhaps vasopressin 
combined with inotropic agent would have secured small intestinal 
blood flow also in the brain death model.  
It is possible than in the near future we will find tools to interrupt 
the inflammatory cascade and prevent fulminant septic shock for 
developing. Until that day, tissue perfusion in septic shock will have 
to be treated with vasoactives, and according to our experiments, 
primarly with norepinephrine and secondarly with vasopressin and 
dobutamine.   
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7 Conclusions 
 
Dopexamine causes selective blood flow redistribution in the 
splanchnic area and reverses deleterious metabolic changes in the 
colon, but not in the stomach, during prolonged endotoxin shock.  
 
• Vasopressin, even at a low dosage, causes systemic and regional 
hypoperfusion, especially to the mesenteric area, in both 
endotoxin shock and brain death models. 
 
• Dobutamine compensates for the deleterious hemodynamic and 
metabolic effects of vasopressin 
 
• Arterial hyperlactatemia associated with epinephrine is not 
explained solely by systemic hypoperfusion. However, 
epinephrine also induces selective hypoperfusion to the gastric 
mucosa in endotoxin shock. 
 
• Norepinephrine is relatively potent in restoring systemic blood 
perfusion in severe endotoxin shock, and also no adverse 
hemodynamic or metabolic effects on the splanchnic area were 
related to the use of norepinephrine.  
 
• Vasopressin is effective in restoring systemic blood pressure, but 
dopamine is superior to vasopressin in maintaining splanchnic 
and especially small bowel blood perfusion in the experimental 
brain death model. 
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Vasoactive agents are frequently 
needed in the treatment of septic 
shock and brain death organ donors. 
We evaluated the differences of 
several vasopressors on splanchnic 
blood perfusion and metabolism. 
Even though the systemic blood 
pressure was restored  effectively, 
the splanchnic hemodynamic and 
metabolic profiles differed remark-
ably between different vasoactive 
agents. The specific regional blood 
perfusion deficits were practically 
impossible to evaluate from the sys-
temic parameters.
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